Note: Descriptions are shown in the official language in which they were submitted.
CA 02318347 2000-07-18
WO 99/41241 PCTIUS99/02966
HETEROCYCLIC TOPOISOMERASE POISONS
$ ('tovernment FLnding
The invention described herein was made with government
support under grant CA-39662 awarded by the National Cancer Institute. The
United States Government has certain rights in the invention.
DNA-topoisomerases are enzymes present in the nuclei of cells
where they catalyze the breaking and rejoining ofDNA strands, controlling the
topological state of DNA. Recent studies also suggest that topoisomerases are
involved in regulating template supercoiling during RNA transcription. There
are two major classes of mammalian topoisomerases. DNA-topoisomerase-I
catalyzes changes in the topological state of duplex DNA by performing
transient single-strand breakage-union cycles. In contrast, mammalian
topoisomerase II alters the topology of DNA by causing a transient enzyme
bridged double-strand break, followed by strand passing and resealing.
Mammalian topoisomerase II has been further classified as Type II a and Type
II
~3. The antitumor activity associated with agents which are topoisomerase
poisons is associated with their ability to stabilize the enzyme-DNA~cleavable
complex. This drug-induced stabilization of the enzyme-DNA cleavable
complex effectively converts the enzyme into a cellular poison.
Several antitumor agents in clinical use have potent activity as
mammalian topoisomerase II poisons. These include adriamycin,
actinomycin D, daunomycin, VP-16, and VM-26 (teniposide or
epipodophyllotoxin).
In contrast to the number of clinical and experimental drugs
which act as topoisomerase II poisons, there are currently only a limited
number
of agents which have been identified as topoisomerase I poisons. Camptothecin
and its structurally-related analogs are among the most extensively studied
topoisomerase I poisons. Recently, bi- and terbenzimidazoles (Chen et.al.,
Cancer Res. 1993, 53, 1332-1335; Sun et al., J. Med. Chem. 1995, 38, 3638-
3644; Kim et al., J. Med. Chem.1996, 39; 992-998), certain
CA 02318347 2000-07-18
WO 99/41241 . PCTlUS99/02966
~~ 2
benzo[c]phenanthridine and protoberberine alkaloids and their synthetic
analogs
(Makhey et al.; Med. Chem. Res. 1995, 5,1-12; Janin et al., J. Med. Chem 1975,
18, 708-713; Makhey et al., Bioorg. & Med. Chem. 1996, 4, 781-791), as well as
the fungal metabolites, bulgarein (Fujii et al., J. Biol. Chem. 1993, 268,
13160-
13165) and saintopin (Yamashita et al.; Biochemistry 1991, 30, 5838-5845) and
indolocarbazoles (Yamashita et al., Biochemistry 1992, 31, 12069-12075) have
been identified as topoisomerase I poisons.
Presently, a need exists for novel and effective anti-cancer agents.
In particular, there is also a need for anti-cancer agents that exhibit
improved
activity, fewer side-effects, or improved selectivity compared to existing
agents.
The present invention provides compounds that exhibit inhibitory
activity against topoisomerase I, and compounds that are effective cytotoxic
agents against cancer cells, including drug-resistant cancer cells.
Accordingly
there is provided a compound of the invention which is a compound of
formula I:
25 wherein
R, and RZ are each independently hydrogen, (C,-C6)alkyl, (C3-
C~cycloalkyl, (C3-C~cycloalkyl(C,-C~alkyl, (C,-C6)alkoxy, (C3-
C6)cycloalkyl(C,-C6)alkoxy, hydroxy, halo, vitro, cyano, mercapto, carboxy,
hydroxy(C1-C6)alkyl, halo(Cl-C6)alkyl, trifluorornethoxy, (C',-C6)alkanoyl,
(C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (C,-C~alkanoyloxy, aryl, heteroaryl,
aryl(C,-C6)alkyl, or heteroaryl(C,-C6)alkyl; or Rt and Rz taken together are
methylenedioxy; or R, and RZ taken together are benzo;
CA 02318347 2000-07-18
WO 99141241 PCTNS99/02966
3
R3, R4, and RS are each independently selected from the group
consisting of hydrogen, (C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkanoyl,
{C,-C6)alkoxycarbonyl, {CZ-C6)alkanoyloxy, aryl, heteroaryl, aryl(C,-C6}alkyl,
and heteroaryl(CI-C6)alkyl;
R6 and R~ are each independently hydrogen, (C,-C6)alkyl, {C3-
C~cycloalkyl, (C3-C6)cycloalkyl(C,-C,;)alkyl, (C,-C6)alkoxy, (C3-
C6}cycloalkyl(C,-C6)alkoxy, hydmxy, halo, nitro, cyano, mercapto, carboxy,
hydroxy(C,-C6)alkyl, halo(C,-C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl,
(C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, or (C,-C6)alkanoyloxy;
R8 is hydroxy, halo, nitro, cyano, mercapto, carboxy, (C,-
C6)alkoxy, (C3-C6)cycloalkyl(C,-C6)allcoxy, -NRaRe, halo(C,-C6)alkyl,
trifluoromethoxy, (C,-C6)alkanoyl, halo(C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl,
(C,-C6)alkylthio, (C,-C6)alkanoyloxy, aryloxy, heteroaryloxy, SR~, or S(O)"Rd;
or Ra is (C,-C6)alkyl substituted by 1, 2, or 3 substituents independently
selected
from the group consisting of hydroxy, nitro, cyano, mercapto, carboxy, (C,-
C6)alkoxy; (C3-C6)cycloalkyl(C,-C6)alkoxy, -NRaRb, trifluoromethoxy, (C,-
C6)alkanoyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (C,-C6)alkanoyloxy,
aryloxy, and heteroaryloxy;
n is 1 or 2;
each of Ra and Rb is independently hydrogen, (C,-C~alkyl, (C,-
C6)alkanoyl, (C,-C6)alkoxycarbonyl, aryl, heteroaryl, aryl(C,-C6)alkyl,
heteroaryl(C,-C6)alkyl, arylcarbonyl, or heteroarylcarbonyl; or R8 and Rb
together with the nitrogen to which they are attached are pyrrolidino,
piperidino,
or morpholino;
R~ is (C,-C6)alkyl, (C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl, aryl,
heteroaryl, aryl(C,-C6)alkyl, heteroaryl(C,-C6)alkyl, arylcarbonyl, halo(C1-
C6)alkyl, or heteroarylcarbonyl;
Rd is (C,-C6)alkyl, (C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl, aryl,
heteroaryl, aryl(C,-C6)alkyl, heteroaryl(C,-C6)alkyl, arylcarbonyl, halo(C,-
C6)alkyl, NReR" or heteroarylcarbonyl; and
I~ and Rf are each independently hydrogen, (C,-C6)alkyl, (C,-
C6)aikanoyl, aryl, heteroaryl, aryl(C,-C6)alkyl, heteroaryl(C,-C6)alkyl,
arylcarbonyl, halo(C,-C6)alkyl, or heteroarylcarbonyl;
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
4
wherein any aryl, heteroaryl, or benzo of R~-R5, R8, and Ra-Rf
may optionally be substituted by l; 2, or 3 substituents independently
selected
from the group consisting of (C,-C6)alkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(C~-C6)alkyl, (C,-C6)alkoxy, (C3-C~cycloalkyl(C~-C6)alkoxy,
hydroxy, halo,.nitro, cyano, mercapto, carboxy, hydroxy(C1-C6)alkyl, halo(C,
C6)alkyl, trifluoromethoxy, (C~-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C,
C6)alkylthio, and {C,-C6)alkanoyloxy;
or a pharmaceutically acceptable salt thereof.
The invention also provides a compound of the invention which is
a compound of formula I:
~~3 " ~ 1N
(I)
wherein
R, and RZ are each independently (C,-C~alkyl, (C~-C6)cycloalkyl,
(C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkoxy, (C3-C6)cycloalkyl{C,-C6)alkoxy,
hydroxy, halo, vitro, cyano, rnercapto, carboxy, hydroxy(C~-C6)alkyl, halo(C,-
C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl, (C,-
C6)alkylthio, (C,-C6)alkanoyloxy, aryl, heteroaryl, aryl(C,-C6)alkyl, or
heteroaryl(C,-C6)alkyl; or R, and RZ taken together are methylenedioxy;
R3, R4, and Rs are each independently selected from the group
consisting of hydrogen, (C,-C6)alkyl, (C3 C6)cycloalkyl, (C,-C~alkanoyl,
(C,-C6)alkoxycarbonyl, (CZ-C6)alkanoyloxy, aryl; heteroaryl, aryl(C~-C~alkyl,
and heteroaryl(C,-C6)alkyl;
Rb and R~ are each independently hydrogen, (C,-C6)alkyl, (C3-
C6)cycloalkyl, {C3-C~cycloalkyl(C~-C~alkyl, (C~-C6)alkoxy, {C3-
C6)cycloalkyl(C,-C6)alkoxy, hydroxy, halo, vitro, cyano, mercapto, carboxy,
CA 02318347 2000-07-18
WO 99141241 PCTIUS99/02966
hydroxy(C,-C6)alkyl, halo(C,-C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl,
(C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, or (C,-C6)alkanoyloxy; and
R$ is hydrogen, (C,-C6)alkyl, aryl, or heteroaryl;
wherein any aryl or heteroaryl of R,-RS and Rg may optionally be
5 substituted by 1, 2; or 3 substituents independently selected from the group
consisting of (C,-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl(C,-C6)alkyl,
(C,-C6)alkoxy, (C3-C6)cycloalkyl(C,-Cb)alkoxy, hydroxy, halo, nitro, cyano,
mercapto, carboxy, hydroxy(C,-C6)alkyl, halo(C,-C6)alkyl, trifluoromethoxy,
(C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, and (C,-
C6)alkanoyloxy;
or a pharmaceutically acceptable salt thereof.
The invention also provides a pharmaceutical composition
comprising a compound of formula I, or a pharmaceutically acceptable salt
thereof; in combination with a pharmaceutically acceptable Garner.
The invention also provides a therapeutic method comprising
inhibiting cancer cells by administering to a mammal (e:g. a human) in need of
such therapy, an amount of a compound of fornnula I, or a pharmaceutically
acceptable salt thereof, effective to inhibit said cancer cells.
The invention also provides a method comprising inhibiting
cancer cells by contacting said cancer cells in vitro or in vivo with an
amount of
a compound of formula I, or a pharmaceutically acceptable salt thereof,
effective
to inhibit said cancer cells, i.e. to inhibit their activity, such as their
ability to
divide, migrate, or proliferate.
The invention also provides a compound of formula I for use in
medical therapy (preferably for use in treating cancer, e.g. solid tumors; or
for
use as an antifungal agent), as well as the use of a compound of formula I for
the
manufacture of a medicament useful for the treatment of cancer, e.g. solid
tumors, and the use of a compound of formula I for the manufacture of a
medicament useful for the treatment of fungal infeaction.
The invention also provides processes and novel intermediates
disclosed herein which are useful for preparing compounds of the invention.
Some of the compounds of formula I are useful to prepare other compounds of
formula I.
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
6
FIG. 1 shows the structure of representative compounds of the invention
and other compounds (1, 6, 9, 14, 17, and 19).
FIG. 2 shows biological data for representative compounds of formula I.
S I~tail~s]"I~,~ripti~n
The following definitions are used, unless otherwise described:
halo is fluorci, chloro, bromo, or iodo. Alkyl, alkoxy, etc. denote both
straight
and branched groups; but reference to an individual radical such as "propyl"
embraces only the straight chain radical, a branched chain isomer such as
"isopropyl" being specifically referred to. Aryl denotes a phenyl radical or
an
ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms
in
which at least one ring is aromatic. Heteroaryl encompasses a radical attached
via w ring carbon of a monocyclic aromatic ring containing five or six ring
atoms
consisting of carbon and one to four heteroatoms each selected from the group
1 S consisting of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or
is H,
O, (C,-C4)alkyl, phenyl or benzyl, as well as a radical of an ortho-fused
bicyclic
heterocycle of about eight to ten ring atoms derived therefrom, particularly a
benzo-derivative or one derived by fusing a propylene, trimethylene, or
tetramethylene diradical thereto.
It will be appreciated by those skilled in the art that compounds of
the invention having a chiral center may exist in and be isolated in optically
active and racemic forms. Some compounds may exhibit polymorphism. It is to
be understood that the present invention encompasses any racemic, optically-
active, polymorphic, or stereoisomeric form, or mixtures thereof, of a
compound
2S of the invention, which possess the useful properties described herein, it
being
well known in the art how to prepare optically active forms (for example, by
resolution of the racemic form by recrystallization techniques, by synthesis
from
optically-active starting materials, by chiral synthesis, or by
chromatographic
separation using a chiral stationary phase) and how to determine topoisomerase
poisoning activity or cytotoxic activity using the standard tests described
herein,
or using other similar tests which are well known in the art.
Specific and preferred values listed below for radicals,
substituents, and ranges, are for illustration only; they do not exclude other
CA 02318347 2000-07-18
WO 99141241 PC'TIUS99/02966
7
defined values or other values within defined ranges for the radicals and
substituents
Specifically, (C,-C6)alkyl can be methyl, ethyl, propyl, isopropyl,
butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C3-C6)cycloalkyl can
be
, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; (C3-C~cycloalkyl(C,-
C6)alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl,
or
2-cyclohexylethyl; (C,-C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy,
butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; {C,-
C6)alkanoyl can be acetyl, propanoyl or butanoyl; halo(C,-C6)alkyl can be
iodomethyl, bromomethyl, chloromethyl, fluoromethyl, trifluoromethyl,
trichloromethyl, chlorodifluoromethyl, dichlorofluoromethyl, 2-chloroethyl, 2-
fluoroethyl, 2,2,2-trifluoroethyl, or pentafluoroethyl; halo(C1-C6)alkanoyl
can be
trifluomacetyl, chlorodifluoroacetyl, dichlorofluoroacetyl, 3,3,3-
trifluompropanoyl, or perfluoropropanoyl; hydroxy(C,-C6)alkyl can be
hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-
hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 4-hydroxybutyl, 1-
hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, or 6-hydroxyhexyl;
(C,-C6)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl,
propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or
hexyloxycarbonyl; {C,-C6)alkylthio can be methylthio, ethylthio, propylthio,
isopropylthio, butylthio, isobutylthio, pentylthio, or hexylthio; {C,-
C6)alkanoyloxy can be formyloxy, acetoxy, propanoyloxy, butanoyloxy,
isobutanoyloxy, pentanoyloxy, or hexanoyloxy; aryl can be phenyl, indenyl, or
naphthyl; and heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl,
oxazoyl,
isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl,
pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl,
isoquinolyl (or its N-oxide) or quinolyl (or its N-oxide).
A specific value for R, is hydrogen. Another specific value for R,
is halo (e.g. bromo).
A specific value for RZ is phenyl, optionally substituted by 1, 2,
or 3 substituents independently selected from the group consisting of (C,-
C6)alkyl, (C,-C6)alkoxy, hydroxy, halo, vitro, cyano, mercapto, carboxy,
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966'~
8
halo(C,-C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl,
(C,-C6)alkylthio, and (C,-C6)alkanoyloxy. Another specific value for RZ is
phenyl.
A specific value for each of R3, R4, and RS is hydrogen.
A specific value for R6 or R~ is (C,-C6)aIkoxy, hydroxy, halo,
vitro, cyano, mercapto, carboxy, hydroxy(C,-C6)alkyl, halo(C,-C6)alkyl,
trifluoromethoxy, (C,-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C,-C6)alkylthio, or
(C,-C6)alkanoyloxy. Another specific value for each of R6 and R, is hydrogen.
A specific value for R8 is hydroxy, halo, vitro, cyano, mercapto,
carboxy, (C,-C6)alkoxy, -NRaRb, halo(C,-C6)alkyl, trifluoromethoxy, (C,-
C~alkanoyl, (C~-C6)alkoxycarbonyl, (C~-C6)alkylthio, or (C~-C6)alkanoyloxy.
Another specific value for Rg is (C,-C~)alkyl substituted by 1, 2, or 3
substituents
independently selected from the group consisting of hydroxy, vitro, cyano,
mercapto, carboxy, (C,-C6)alkoxy; -NRaRe, trifluoromethoxy, (C,-C6)alkanoyl,
(C,-C6)alkoxycarbonyl, (C~-C6)alkylthio, and (C~-C6)alkanoyloxy. Another
specific value for R$ is (C,-C6)alkyl substituted by hydroxy, vitro, cyano,
mercapto; carboxy, (C,-C6)alkoxy, -NR~Rb, trifluoromethoxy, (C,-C6)alkanoyl,
(C,-C6)alkoxycarbonyl, (C~-C6)alkylthio; or (C,-C6)alkanoyloxy.
A specif c value for R8 is hydroxy, halo, vitro, cyano, mercapto,
carboxy, (C,-C6)alkoxy, (C3-C6)cycloalkyl(C,-C6)alkoxy; -NRaRe, halo(C,-
C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl, (C,-C6)alkoxycarbonyl, (C,-
C6)alkylthio, (CI-C6)alkanoyloxy, arylaxy, or heteroaryloxy; or Rg is (C,-
C6)alkyl substituted by l, 2, or 3 substituents independently selected from
the
group consisting of hydroxy, vitro, cyano, mercapto, carboxy, (C,-C6)alkoxy,
(C3-C6)cycloalkyl(C~-C6)alkoxy, -NRaRti, trifluoromethoxy, (C,-C6)alkanoyl,
(C,-C6)alkoxycarbonyl, (C~-C6)alkylthio, (C~-C~alkanoyloxy, aryloxy, and
heteroaryloxy.
A specific value for R~ is (C~-C6)alkyl.
A specific value for Rd is (C,-C6)alkyl, or NReRf
A specific value for Re or R f is hydrogen, (C,-C~alkyl, aryl, or
aryl(C,-C6)alkyl.
A more specific value for R$ is trifluoromethyl,
chlorodifluoromethyl, dichlorofluoromethyl, 2,2,2-trifluoroethyl,
perfluoroethyl,
CA 02318347 2000-07-18
WO 99/41241 PCTNS99102966
9
trifluoromethoxy, cyano, halo, carboxy, (C,-C6}alkoxycarbonyl, halo(Cl-
C~alkanoyl, or S(O)"Rd.
A preferred value for R~ is hydrogen; for R2 is phenyl; and for Rg
is halo or trifluoromethyl. A more preferred value for R$ is trifluoromethyl.
A preferred gioup of compounds of formula I wherein Rl and RZ
are each halo (e.g. bromo).
Processes for preparing compounds of formula I are illustrated by
the following procedures in which the meanings of the generic radicals are as
given above unless otherwise qualified.
A compound of formula I wherein R8 is hydmxy can be prepared
by treating an intermediate of formula II:
1
(n)
with urea, for example, using conditions similar to those described in Example
1.
A compound of fornnula I wherein Rg is mercapto can be prepared
by treating an intermediate of formula II with ethylxanthic acid potassium
salt,
for example, using conditions similar to those described in Example 2.
A compound of formula I wherein Rg is amino can be prepared by
treating an intermediate of formula II with cyanogen bromide, for example,
using
conditions similar to those described in Example 3.
Compounds of formula I can generically be prepared by reacting
an intermediate diamine of formula III with an intermediate aldehyde of
formula IV.
CA 02318347 2000-07-18
WO 99/41241 PCT/l1S99/02966
NH2 OH ~,~~ N
I
$ NH2 ~N
R7 'RS
(III) (IV)
10 The reaction can conveniently be carried out under conditions similar to
those
described in the Examples (e.g., Example 4).
Compounds of formula I can also generally be prepared by
reacting an intermediate diamine of formula V with an aldehyde of formula VI.
R2 / ~2 OH
~ + N
R~
R6
N
I
(V) (~)
The reaction can conveniently be performed under conditions similar to those
described in the Examples (e.g. Example 12).
Compounds of formula a comprising a hydroxy group can be
prepared from a corresponding compound of formula I comprising a methoxy
group by treatment with boron tribromide, for example using conditions similar
to those described in Example 7.
Compounds of formula I comprising a amino group can be
prepared from a corresponding compound of formula I comprising a acetamido
group by hydrolysis using conditions similar to those described in Example 8.
Intermediates of formula II, III, IV, V, and VI wherein Rl-R8
have any of the values, specific values, or preferred values defined herein
for the
corresponding radicals in a compound of formula I, are particularly useful for
preparing compounds of formula I.
CA 02318347 2000-07-18
WO 99141241 PCT/US99/02966
11
In cases where compounds are sufficiently basic or acidic to form
stable nontoxic acid or base salts, administration of the compounds as salts
may
be appropriate. Examples of pharmaceutically acceptable salts are organic acid
addition salts formed with acids which form a physiological acceptable anion,
for example, tosylate, methanesulfonate, acetate, citrate, malonate,
tartarate,
succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
Suitable inorganic salts may also be formed; including hydrochloride, sulfate,
nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard
procedures well known in the art, for example by reacting a sufficiently basic
compound such as an amine with a suitable acid aftbrding a physiologically
acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or
alkaline earth metal (for example, calcium) salts of carboxylic acids can also
be
made.
The compounds of formula I can be formulated as pharmaceutical
compositions and administered to a mammalian host, such as a human patient in
a variety of forms adapted to the chosen route of administration, i.e., orally
or
parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered,
e.g., orally, in combination with a pharmaceutically acceptable vehicle such
as
an inert diluent or an assimilable edible carrier. They may be enclosed in
hard or
soft shell gelatin capsules, may be compressed into tablets, or may be
incorporated directly with the food of the patient's diet. For oral
therapeutic
administration, the active compound may be combined with one or more
excipients and used in the form of ingestible tablets, buccal tablets,
troches;
capsules, elixirs, suspensions, syrups, wafers, and the like. Such
compositions
and preparations should contain at least 0.1% of active compound. The
percentage of the compositions and preparations may, of course, be varied and
may conveniently be between about 2 to about 60% of the weight of a given unit
dosage form. The amount of active compound in such therapeutically useful
compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain
the following: binders such as gum tragacanth, acacia, corn starch or gelatin;
CA 02318347 2000-07-18
WO 99141241 PCT/US99/02966
i2
excipients such as dicalcium phosphate; a disintegrating agent such as corn
starch, potato starch, alginic acid and the like; a lubricant such as
magnesium
stearate; and a sweetening agent such as sucrose, fructose, lactose or
aspartame
or a flavoring agent such as peppermint, oil of wintergreen, or cherry
flavoring
may be added. When the unit dosage form is a capsule, it may contain; in
addition to materials of the above type, a liquid carrier, such as a vegetable
oil or
a polyethylene glycol. Various other materials may be present as coatings or
to
otherwise modify the physical form of the solid unit dosage form. For
instance,
tablets, pills, or-capsules may be coated with gelatin, wax, shellac or sugar
and
the like. A syrup or elixir may contain the active compound, sucrose or
fructose
as a sweetening agent, methyl and propylparabens as preservatives, a dye and
flavoring such as cherry or orange flavor. Of course, any material used in
preparing any unit dosage form should be pharmaceutically acceptable and
substantially non-toxic in the amounts employed. In addition, the active
compound may be incorporated into sustained-release preparations and devices.
The active compound may also be administered intravenously or
intraperitoneally by infusion or injection. Solutions of the active compound
or
its salts can be prepared in water, optionally mixed with a nontoxic
surfactant.
Dispersions can also be prepared in glycerol, liquid polyethylene.glycols,
triacetin, and mixtures thereof and in oils. Under ordinary conditions of
storage
aid use, these preparations contain a preservative to prevent the growth of
microorganisms.
The pharmaceutical dosage forms suitable for injection or
infusion can include sterile aqueous solutions or dispersions or sterile
powders
comprising the active ingredient which are adapted for the extemporaneous
preparation of sterile injectable or infusible solutions or dispersions,
optionally
encapsulated in liposomes. In all cases, the ultimate dosage form should be
sterile, fluid and stable under the conditions of manufacture and storage. The
liquid carrier or vehicle can be a solvent or liquid dispersion medium
comprising, for example, water, ethanol, a polyol (for example, glycerol,
propylene glycol, liquid polyethylene glycols, and the like), vegetable oils,
nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity
can
be maintained, for example, by the formation of liposomes, by the maintenance
CA 02318347 2000-07-18
WO 99141241 PCT/US99/0~966
13
of the required particle size in the case of dispersions or by the use of
surfactants.
The prevention of the action of microorganisms can be brought about by various
antibacterial and antifungal agents, for example, parabens, chlorobutanol,
phenol, sorbic acid, thiomersal, and the like. In many cases,.it will be
preferable
to include isotonic agents, for example, sugars, buffers or sodium chloride.
Prolonged absorption of the injectabie compositions can be brought about by
the
use in the compositions of agents delaying absorption, for example, aluminum
monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the
active compound in the required amount in the appropriate solvent with various
of the other ingredients enumerated above, as required, followed by filter
sterilization. In the case of sterile powders for the preparation of sterile
injectable solutions, the preferred methods of preparation are vacuum drying
and
the freeze drying techniques, which yield a powder of the active ingredient
plus
any additional desired ingredient present in the previously sterile-filtered
solutions.
1"or topical administratian, the present compounds may be applied
in pure form, i.e., when they are liquids. However, it will generally be
desirable
to administer them to the skin as compositions or formulations, in combination
with a dermatologically acceptable carrier, which may be a solid or a liquid.
Useful solid earners include finely divided solids such as talc,
clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid
carriers include water, alcohols or glycals or water-alcohol/glycol blends, in
which the present compounds can be dissolved or dispersed at effective levels,
optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances
and additional antimicrobial agents can be added to optimize the properties
for a
given use. The resultant liquid compositions can be applied from absorbent
pads, used to impregnate bandages and other dressings, or sprayed onto the
affected area using pump-type or aerosol sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts
and esters, fatty alcohols, modified celluloses or modified mineral materials
can
also be employed with liquid carriers to form spreadable pastes, gels,
ointments,
soaps, and the like, for application directly to the skin of the user.
CA 02318347 2000-07-18
WO 99/41241 PCTNS99I02966
14
Examples of useful dermatological compositions which can be
used to deliver the compounds of formula I to the skin are known to the art;
for
example, see Jacquet et al. (U.S. Pat. No. 4;608,392), Geria (I1.S. Pat. No.
4,992,478), Smith et al. (LJ.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat.
No.
4,820,508).
Useful dosages of the. compounds of formula I can be determined
by comparing their in vitro activity, and in vivo activity in animal models.
Methods for the extrapolation of effective dosages in mice, and other animals,
to
humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the compounds) of formula I in a
liquid composition, such as a lotion, will be from about 0.1-25 wt-%,
preferably
from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition
such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5
wt-%.
The amount of the compound, or an active salt or derivative
thereof, required for use in treatment will vary not only with the particular
salt
selected but also with the route of administration, the nature of the
condition
being treated and the age and condition of the patient and will be ultimately
at
the discretion of the attendant physician or clinician.
In general, however, a suitable dose will be in the range of from
about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body
weight per day, such as 3 to about 50 mg per kilogram body weight of the
recipient per day, preferably in the range of 6 to 90 mg/kg/day, most
preferably
in the range of 15 to 60 mg/kg/day.
The compound is conveniently administered in unit dosage form;
for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most
conveniently, 50 to 500 mg of active ingredient per unit dosage form.
Ideally, the active ingredient should be administered to achieve
peak plasma concentrations of the active compound of from about 0.5 to about
75 pM, preferably, about 1 to 50 pM, most preferably, about 2 to about 30 pM.
This may be achieved, for example, by the intravenous injection of a 0.05 to
5%
solution of the active ingredient, optionally in saline, or orally
administered as a
bolus containing about 1-100 mg of the active ingredient. Desirable blood
levels
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or
by intermittent infusions containing about 0.4-15 mg/kg of the active
ingredient(s).
The desired dose may conveniently be presented in a single dose
5 or as divided doses administered at appropriate intervals, for example, as
two,
three, four or more sub-doses per day. The sub-dose itself may be further
divided, e.g., into a number of discrete loosely spaced administrations; such
as
multiple inhalations from an insufflator or by application of a plurality of
drops
into the eye.
10 The ability of a compound of the invention to effect
topoisomerase I mediated DNA cleavage can be determined using
pharmacological models that are well known to the art, for example, using a
model like Test A described below.
15 T_~~st A. Topoisomerase I Cleavage Assay.
Representative compounds of the invention were evaluated in a
cleavage assay using recombinant topoisomerases I. This assay was preformed
as described by B. Gatto et al. Cancer Res., 1996, 56, 2795-2800. Human
topoisomerase I was isolated as a recombinant fusion protein using a T7
expression system: Plasmid YEpG was purified by the alkali lysis method
followed by phenol deproteination and CsCI/ethidium isopycnic centrifugation
as described by Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning,
a
Laboratory Manual; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY
1982; pp 149-185. The end-labeling of the plasmid was accomplished by
digestion with a restriction enzyme followed by end-filling with Klenow
polymerase as previously described by Liu, L. F.; Rowe, T. C.; Yang, L:;
Tewey,
K. M.; Chen, G. L. "Cleavage of DNA by mammalian topoisomerase II," J. Biol.
Chem. 1983, 258, 15365. ICso values were calculated after 4 days of continuous
drug exposure. Topoisomerase I cleavage values are reported as REC, Relative
Effective Concentration (i.e., concentrations relative to compound 5, whose
value is arbitrarily assumed as 1) that is able to produce the same cleavage
on the
plasmid DNA in the presence of human topoisomerase I.
CA 02318347 2000-07-18
WO 99141241 PCT/US99/02966
16
The cytotoxic effects of a compound of the invention can be
determined using pharmacological models that are well known to the art, for
example, using a model like Test B described below.
T~st_B.. Cytotoxicity Assay.
Cytotoxicity was determined using the MTT-microtiter plate
tetrazolinium cytotoxicity assay (MTA) (See Chen A.Y. et al. Cancer Res. 1993,
53, 1332; Mosmann, T. J., J. Immunol. Methods 1983, 65, 55; and Carmichael, J.
et al. Cancer Res. 1987, 47, 936). The human lymphoblast RPMI 8402 and its
camptothecin-resistant variant cell line, CPT-KS were provided by. Dr. Toshiwo
Andoh (Aichi Cancer Center Research Institute, Nagoya; Japan) (see Andoh, T.;
Okada, K. "Drug resistance mechanisms of topoisomerase I drugs," Adv. in
Pharmacology 1994, 29B; 93. The cytotoxicity assay was performed using 96-
well microtiter plates. Cells were grown in suspension at 37 °C in 5%
COZ and
maintained by regular passage in RPMI medium supplemented with 10% heat-
inactivated fetal bovine serum, L-glutamine (2 mM), penicillin {100 U/mL), and
streptomycin (0.1 mg/mL). For determination of ICsa, cells were exposed
continuously with varying concentrations of drug and MTT assays were
performed at the end of the fourth day.
Data from Test A and Test B is shown in Figure 2 for
representative compounds of the invention.
Using a protocol similar to Test B, the cytotoxicity of
compound 5 and compound 22 was evaluated in other tumor cell lines. The data
is presented in Table 1.
CA 02318347 2000-07-18
WO 99141241 PCTNS99/02966
17
Compound Cell Line Organ Site Cytotoxicity
IC50
yM~
5 MDA-MB-435 Mammary 0.08
5 MCF7 Mammary >30
5 OVCAR-3 Ovarian 0:26
S SK-OV-3 Ovarian 0.55
5 PC-3 Prostate 0.06
5 DU-145 Prostate 0.59
5 SF-268 Glioblastoma 0.26
5 SF-295 Giloblastoma 0.23
5 NCI-H82 Large Cell 0.26
Lung
5 NCI-H23 Small Cell 2.55
Lung
5 HT29 Colon 2.65
5 KB3-1 Epidermal Oral0.01
5 KBV-1 Oral MDR1 11.0
22 MDA-MB-435 Mammary 0.15
22 MCF7 Mammary >100
22 OVCAR-3 Ovarian 6.31
22 SK-OV-3 ~ Ovarian 1.36
22 PC-3 Prostate 0.23
22 DU-145 Prostate 2.04
22 SF-268 Glioblastoma 2:27
22 SF-295 Giloblastoma 0.25
22 NCI-H82 Large Cell 0.79
Lung
22 NCI-H23 Small Cell >100
Lung
22 HT29 Colon > 100
Gampounds of formula l are potent topoisomerase I poisons.
Additionally, compounds of formula I have been shown to exhibit cytotoxic
activity against RPMI 8402 cancer cells, camptothecin resistant CPT-KS cells,
and numerous other tumor cells. Accordingly, compounds of formula I are
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
18
useful as cytotoxic agents, for the treatment of cancers, and in particular,
solid
mammalian tumors or hematologic malignancies. Compounds of the invention
are also useful as pharmacological tools for in vitro and in vivo study of
topoisomerase function and activity.
As used herein, the term "solid mammalian tumors" includes
cancers of the head and neck, lung, mesothelioma, mediastinum, esophagus,
stomach, pancreas, hepatobiliary system, small intestine, colon, rectum, anus;
kidney, ureter; bladder, prostate, urethra, penis, testis, gynecological
organs,
ovarian, breast, endocrine system, skin central nervous system; sarcomas of
the
soft tissue and bone; and melanoma of cutaneous and intraocular origin. The
term "hematological malignancies" includes childhood leukemia and
lymphomas, Hodgkin's disease, lymphomas of lymphocytic and cutaneous
origin, acute and chronic leukemia, plasma cell neoplasm and cancers
associated
with AIDS. The preferred mammalian species for treatment are humans and
domesticated animals.
The compounds are also expected to exhibit some of the other
bioa.ctivities observed for topoisomerase inhibitors, such as antibacterial,
antifungal, antiprotozoal, antielrnintic and/or antiviral activity. In
particular, the
compounds may exhibit antifungal activity. Thus, the invention also provides a
therapeutic method to treat fungal infection comprising administering to a
mammal afflicted with a fungal infection, an effective antifungal amount-of a
compound of the formula I, or a pharmaceutically acceptable salt thereof.
The invention will now be illustrated by the following non-
limiting Examples, wherein unless otherwise stated: melting points were
determined with a Thomas-Hoover Unimelt capillary melting point apparatus;
column chromatography refers to flash chromatography conducted on SiliTech
32-63 ~.m, (ICN Biomedicals, Eschwegge, Ger.) using the solvent systems
indicated; infrared spectral data (IR) were obtained on a Perkin-Elmer 1600
Fourier transform spectrophotometer and are reported in cm 1; proton (1H NMR)
and carbon ('3C NMR) nuclear magnetic resonance were recorded on a Varian
Gemini-200 Fourier Transform spectrometer; NMR spectra (200 MHZ 1H and 50
MHZ- '3C) were recorded in the deuterated solvent indicated with chemical
shifts
reported in 8 units downfield from tetramethylsilane (TMS); coupling constants
CA 02318347 2000-07-18
WO 99/41241 PCT/US99102966
19
are reported in hertz (Hz); mass spectra were obtained from Washington
University Resource for Biomedical and Bio-organic, Mass Spectrometry within
the Department of Chemistry at Washington University, St. Louis, MO; and
combustion analyses were performed by Atlantic Microlabs, Inc., Norcross, GA,
and were within t 0.4% of the theoretical value.
Examgl~l.. 5-Phenyl-2-[2'(2"-hydroxybenzimidazol-5"-yl)benzimidazol-
S'-yl]benzimidazole (2).
5-Phenyl-2-[2'-(3,4-diaminophenyl)benzimidazol-
5'yl]benzimidazole, (29.7 mg, 0.07 mmol) and urea (6 mg, O.l .mmol) were
dissolved in DMF {0.4 ml). The mixture was refluxed at 150 °C for 7
hours.
The cooled reaction mixture when concentrated in vacuo and washed with water
provided 27.6 mg (88%) of pure yellow solid; mp > 280 °C; IR (KBr)
3382,
3133, 1693, 1475, 1444, 1279; 'H NMR (DMSO-db + 3 drops CF3COOH) 8 7.3
(d,IH,J= 8.14), 7.46-7.80 (m,3H), 7.80 (d,2H,J=8.1), 7.89-8.01(m,4H); 8.05-
8.14
(m,2H), 8.32 (d, l H,J=8.34), 8.63 (s, l H), 11.35 (s, l H); '~C NMR (DMSO-d6
+ 3
drops CF3COOH) 8 108.07, 109.55, 111.78, 114.03, 114.57, 114.62, 115.3,
120.21, 122.53, 125.45, 125.82, 127.42, 128.1, 129.26, 130.81, 131.59, 132.66,
132.87, 135.15, 135.33, 139.20, 139.61, 149.32, 153.14, 155.71; HRMS (FAB)
calculated for C2~H,9N6 {MH+) 443.1620 found 443.1625.
The intermediate 5-phenyl-2-[2'-(3,4-diaminophenyl)-
benzimidazol-5'yl]benzimidazole was prepared as follows.
a. 5-Phenyl-2-[2'-(3,4-diaminophenyl)benzimidazol-5'yl]benzimidazole.
A solution of 5-phenyl-2-[2'-{3,4-dinitrophenyl)benzimidazol-
5'yl]benzimidazole (75 mg, 0.16 mmol) in ethyl acetate (50 mL) was reduced by
hydrogenation over lU% Pd/C (15 mg) for 90 minutes. The resulting solution
was passed'through a bed of Celite and the ethyl acetate was removed to give
the
diamine, which was used without further purification.
The starting S-phenyl-2-[2'-(3,4-dinitrophenyl)benzimidazol-
5'yl]bent-imidazole can be prepared as described by J.S. Kim et aI. J. Med.
Chem. 1997, 40, 2818-2824.
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
Exampl~2.. 5-Phenyl-2-[2'-(2"-mercaptobenzimidazol-5"-
yl)benzimidazol-5'-yl] benzimidazole (3).
5-Phenyl-2-[2'-(3,4-diaminophenyl)benzimidazol-5'yl]-
benzimidazole, (59.4 mg, 0.14 mmol) and ethylxanthic acid potassium salt (25.1
5 mg, 0.16 moral) were refluxed in ethanol (1 ml) and distilled water (0.1 ml)
overnight. The cooled reaction mixture was acidified to pH 3 with glacial
acetic
acid, volume condensed in vacuo and purified directly by column
chromatography. Elution with (40-100%) ethyl acetate/n-hexanes provided 69%
of yellow solid; mp > 280 °C; IR (KBr) 3089, 2926, 2851, 1712, 1624,
1549,
10 1449, 1380, 1274, 1186, 1079; 'H IVM:R (DMSO-db+ 3 drops CF3COOH) 8 7.33-
7.42 (m,2H), 7.48-7.63 (t,4H), 7.71-7.82 (m,4H), 7.89 {s,IH), 8.04-8:06
(m,lH),
8.1-8.24 (m,lH), 8.42 (d,lH,J=2.4);'3C NMR (DMSO-d~+ 3 drops CF3COOH)
8 107.37,107.15, 109.2, 109.68, 111.81, 111.73, 113.31, 113.53, 114.57,
114.64, 114.68, 115.56, 125.26, 127.44, 128.16, 129.33, 131.64, 132.93,
133.27,
15 139.1, 136.61, 139.62, 149.51, 152.94, 171.13; HRMS (FAB) calculated for
CZ,H,9N6S (MHO 459.1392, found 459.1403.
E~m~. 5-Phenyl-2-[2'-(2"-aminobenzimidazol-5"-yl)benzimidazol-5'-
yl] benzi~idazole {4).
20 5-Phenyl-2-[2'-(3,4-diaminophenyl)benzimidazol-
5'yl]benzimidazole, (66 mg, 0.16 moral) was dissolved in DMF (0.2 ml) and
methanol (1 ml), and was added to cyanogen bromide (10% solution in water,
0.33 ml, 0.63 mmol). The reaction mixture was stirred overnight at room
temperature. The mixture was concentrated under reduced pressure. Compound
was recrystallized from methanol to give 47% of pale brown solid; mp > 280
°C;
IR (KBr) 3352, 3052, 2926, 1680, 1624, 1574, 1461, 1261,679; 'H NMR
(DMSO-db+ 3 drops CF3COOH) S 7.46-7.62 (m,3H), 7.79 (d,2H,J=7.26), 7.87-
7.96 (m,2H), 7.99-8.01 (m,2H),-8.20-8.26 (m,2H), 8.31 (s,lH), 8.72
(d,2H,J=9.12);'3C NMR (DMSO-db+ 3 drops CF3COOH) b 107.38, 110.89,
1 I 1.75, 111.78, 114.67, 115. / 3, 115.24, 115.92, 123.59, 125.58, 126.84,
127.5,
127.53, 127.57, 127.76, 128.2, 129.43, 130.86, 131.87, 133.13, 138.74, 139.74,
150.10, 152.14, 153.42; HRMS (FAB) calculated for CZ~HZ°N~ (MH+)
442.1780
found 442.1776.
CA 02318347 2000-07-18
WO 99/41241 PC'TNS99/02966
21
Rx mnle 4. 5-Phenyl-2-[2'(2"-trinuoromethylbenzimidazol-5"-yl)
benzimidazol-5'-yl]benzimidazole (5).
5-Phenyl-2-[3,4-diaminophenylJbenzimidazole (0.160 g, 0.53
mmol) was heated with 5-formyl-2-trifluoromethylbenzimidazole (0.12 g, 0.54
mmol) in nitrobenzene (4 mL) at 145 °C overnight. Nitrobenzene was
removed
using a Kugelrohr and the compound purified by column chromatography. (1-
16%) methanol/ethyl acetate provided 40% pure yellow compound; mp >
280 °C; IR (KBr) 3047, 2927, 1698, 1626, 1543, 1440, 1287, 1158;'H NMR
{DMSO-db+ 3 drops CF3COOH) 8 7.44-7.59 {m,3H), 7.79 (d,2H,J=7.04), 7.87-
8.01 (m,2H), 8.05-8.09 (m,2H), 8.15-8.19 (m,lH), 8.29-8.35 (m,2H), 8.70
(m,2H); '3C NMR (DMSO-d~+ 3 drops CF3COOH) 8 111.79, 114.68, 114.92,
115.85, 117.53, 117.58, 118.37, 118.41, 119.58, 120.46, 124.14, 124.79,
125.71;.
125.74, 127.47, 128.18, 129.36, 131.73, 132.99, 134.93, 137.44, 138.97,
139.02,
139.07, 139.66, 140.34, 149.81, 153.46; HRMS (FAB) calculated for C28H,8N6F3
(MH+) 495.1545 found 495.1543.
The intermediate 5-formyl-2-trifluoromethylbenzirnidazole was
prepared as follows.
a. ~ 3,4-Diaminobenzonitrile. 4-Amino-3-nitxobenzonitrile (3 g, 18.4
mmol) in ethyl acetate (120 ml) was reduced by hydrogenation using 45 psi of
HZ
and 10 % Pd-C (300 mg) for 1.5 hr. After passing through a bed of celite, the
solvent was removed in vacuo and 2.43 g (99 %) of white solid was obtained; mp
144-145 °C; IR (KBr) 3431, 2726, 2211, 1861, 1631, 1311, 1149, 722; 'H
NMR
(CDCl3) a 3.18-3.87 {'brs, 4H), 6.68 (d, 1H, J=8.06), 6.94 (d,lH,J=1.74), 7.b2-
7.27
(dd,lH,J=1.78,8.06);'3C NMR (CDC13) b 100.27, 115.86, 119.52, 122.19, 125.66,
135.94, 142.52; The crude diamine obtained was typically used without further
purification.
b. 5-Cyano-2-trifluoromethylbenzimidazole. 3,4
Diaminobenzonitrile (200 mg, 1.5 mmol) was refluxed with trifluoroacetic acid
(0.3 ml) for 6 hours. The mixture was neutralized with 2 N NaOH and extracted
with ethyl acetate. The ethyl acetate layer was dried over anhydrous NazS04.
Column with (0-10 %) ethyl acetate/n-hexanes gave 88% of pure white
CA 02318347 2000-07-18
WO 99/41241 PCT/US99102966
22
compound; mp 182-183 °C; 'H NMR (DMSO-db + 3 dmps CF3COOH) S 7.72 -
7.77 (lH,dd,J=1.46,8.56), 7.88 (d,lH, 8.42), 8.35 (s,lH);'3C NMR (DMSO-db +
3 drops CF3COOH) b 106:47, 106.64, 112.36; 117.31, 118.09, 119.44, 123.53,
123.81, 127.47; Anal. calculated for CgH4N3F3: C; S 1.20, H; 1.91, N; 19.90,
S found C; S 1.45, H; 2.03, N; 19.68.
c. 5-Formyl-2-triflnoromethylbenzimidazole. S-Cyano-2-
trifluoromethyl-benzimidazole (196 mg, 0.93 mmoi) was refluxed with HCOOH
(14 m1), HZO (S ml) and Ni-Al (0.9 g) catalyst for 6 hours. The hot reaction
mixture was filtered through celite and concentrated in vacuo. The solution
was
basified with 2N NaOH. Extraction with ethyl acetate followed by drying over
anhydrous sodium sulfate and concentration of the ethyl acetate layer in vacuo
gave the crude aldehyde. Purification was achieved by column chromatography.
Elution with 10/90 ethyl acetate%n-hexanes gave 41 % of pure white compound;
mp 178-179 °C; IR (ICBr) 3210; 2737, 1699, 1 SS2, 1328, I 187 (d), 986;
'H
NMR (DMSO-db + 3 drops CF3COOH} b 7.87-7.95 (m, 2H), 8.34(s,lH), 10.11
(s,lH).'3C NMR {DMSO-d6 + 3 drops CF3COOH) 8 106.63, 112.35, 116.72,
118.08, 121.87, 123.80, 124.04, 132.95, 192.65; HRMS (EI) calculated for
CgHSNZOF3 m/z 214.0354 found 214.0348.
The intermediate 4-amino-3-nitrobenzonitrile used in subpart a
above is commercially available (Aldrich Chemical Company)
The intermediate S=phenyl-2-[3,4-diaminophenyl]benzimidazole
was prepared as follows.
2S
d. 5-Phenyl-2-[3;4-diaminophenyl]benzimidazole. S-Phenyl-2-
[3,4-nitrophenyl]benzimidazole (S80 mg, 1.6 mmol) was dissolved in 100 ml
ethyl acetate and hydrogenation was carried out using 10% Pd/C ( 100 mg} for
1.S hours. The reaction mixture was passed through a bed of celite and the bed
washed with methanol. The washings were concentrated in vacuo to yield (477
mg, 1.59 mmol) of the crude diamine in 98 % yield. The diamine was not
characterized but used without purification; 'H NMR (DMSO-db + 3 drops
CA 02318347 2000-07-18
WO 99/41241 PCT/US99/02966
23
CF3COOH) 8 4.70 (brs,2H), 4.96 {brs, 2H), 6.62 {d,lH,8.02), 7.37 (m,BH), 7.53
(m,2H).
Fx~amgl~. 5-Phenyt-2-[2'-(2"-hydroxymethylbenzimidazol-5"-
yt)benzimidazol-5'-yl]benzimidazole (7).
S-Phenyl-2-[3,4-diaminophenyl]benzimidazole (178 mg, 0.6
mmol) and S-formyl-2-hydroxymethyl benzimidazole (104.2 mg, 0.6 mmol)
were condensed in nitrobenzene (10 ml) overnight at 145 °C.
Nitrobenzene was
removed from the reaction mixture with a Kugelrohr and the compound was
purified directly by column chromatography. Elution with (1-18 %)
methanol/ethyl acetate provided 62% of yellow solid; mp > 280 °C; IR
(Nujol)
3406, 2922, 2725, 1631, 1553, 14E 1, 1377; 'H NMR (DMSO-d6~ 3 drops
CF3COOH) 8 5.1 {s,2H), 7.45-7.59 (m,3H), 7.79 (d,2H,J=6.96), 8.23-8.28
(m,lH), 8.47 (d,lH, J=8.59), 8.68 (s,2H);'3C NMR (DMSO-d6+ 3 drops
CF3COOH) 8 SS.80, 111.69,113.68,114.59, 115.32, 115.77, 116.21, 118.31,
123.77, 124.52, 125.21, 125.61, 127.47, 127.49, 127.54, 128.14,129.38, 131.64,
131.89, 132.91, 133.54, 137.66,138.86, 139.68, 140.13, 150.25, 153.37, 157.62;
HRMS (FAB) calculated for CZ$HZ~N60 {MHO 457.1777 found 457.1774.
The intermediate 5-formyl-2-hydroxymethyl benzimidazole was
prepared as follows.
a. 5-Cyano-2-hydroxymethylbenzimidazole. 3,4
Diaminobenzonitrile (0.2 g, 1.50 mmol) was heated with glycolic acid (0.18 g,
2.37 mmol) in HCl (1.5 ml of4N) for 2 hours. After neutralization with 2M
sodium carbonate the product was extracted into ethyl acetate, dried over
anhydrous NazS04 and concentrated in vacuo to give a white colored solid. The
compound was purified by column chromatography. Elution with (75-100%)
ethyl acetate/n-hexanes gave 65.5% (133 mg, 0.76 mmol) ofpure compound; mp
172-173 °C;1R (Nujol) 3350, 2928, 2219, 1621, 1536, 1302, 1217, 1036,
815;
'H NMR (DMSO-d6 + 3 drops CF3COOH) b 4.88 (s,2H), 7.52-7.57
(dd,lH,J=1.46,8.38), 7.69 {d,IH,J=8.36), 7.95 (s,lH), "C NMR (DMSO-db + 3
drops CF3COOH) b 55.81, 107.99, 115.68, 118.64, 119.50, 129.00, 131.50,
134.39; HRMS (EI) calculated for CgH,N30 (m/z) 173.0590 found 173.0590.
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
24
b. 5-Formyl-2-hydroxymethylbenzimidazole. Ni-A1 (1.2 g) was
added to a solution of 5-cyano-2-hydroxymethylbenzimidazole (0.17 g, 0.97
mmol) in HCOOH (17 ml) and water (1.6 ml). The reaction mixture was heated
at 95 °C for 5 hours. The hot mixture was filtered through a bed of
celite and the
reaction flask and the celite bed rinsed with water and then methanol. The
combined solution was concentrated in vacuo. After addition of water to this
residue, a white precipitate was formed. The pH of this suspension was
adjusted
to 9 by dropwise addition of 2N NaOH. The product was obtained by extraction
with ethyl acetate. The ethyl acetate extract was dried over anhydrous Na2S04
and concentrated in vacuo to give a pure white product (61 % yield); mp 189-
190
°C; IR (KBr) 3309, 2924, 1674, 1619, 1434, 1291, 1073, 808;'H NMR (DMSO-
db + 3 drops CF3COOH) b 5.07 (s,2H), 7.94 (d,lH,J=8.68), 8.04-8.09
(dd,1 H,J=1.34, 8.51 ), 8.32 (s,1 H), 10.4 (s,1 H); '3C NMR (DMSO-db + 3 drops
CF3COOH) b 55.76, 114.95, 116.81, 126.03, 131.45, 133.89, 135.11, 192.31;
HRMS (EI) calculated for C9H8N202 m/z 176.0586 found 176.0586..
Exatzi~pl~6. 5-Phenyl-2-[2'-[2"-[2-(N-benzoyl)aminomethyl]benzimidazol-
5"-yl]benzimidazol-5'-yl]benzimidazole (8).
5-Phenyl-2-[3,4-diaminophenyl]benzimidazole (75 mg, 0.25
mmol) and 5-formyl- 2-[(N-benzoyl)aminomethyl]benzimidazole (70 mg, 0.25
mmol,) were heated in nitrobenzene (6 inl) at 145 °C overnight.
Nitrobenzene
was removed with a Kugelrohr and the compound was loaded on a column. (2-
20%) methanollethyl acetate gave 45% yellowish compound; mp > 280 °C;
IR
(KBr) 3204, 1637, 1542, 1442, 1384, 1292, 1026, 818; ~H NMR (DMSO-db+ 3
drops CF3COOH) 8 7.46-7.66 (m,6H), 7.80 (d, 2H, J=7.06), 7.87-8.1 (m, 7H),
8.21-8.25 (m,lH), 8.43-8.48 (m,lH), 8.67 (s,2H);'3C NMR (DMSO-db+ 3 drops
CF3COOH) 8 36.65, 107.37, 11 I.73, 114.53, 114.58, 115.26, 115.49, 116.0/,
119.47, 122.49, 124.81, 125.56, 126.72, 127.41, 127.83, 128.04, 128.07,
128.54,
129.25, 131.56, 131.87, 132.12, 132.84, 133.17, 134.11, 136.21, 137.76,
139.08,
139.66, 149.67, 152.62, 155.64, 167.60; HRMS (FAB) calculated for
C3sHz6N~0 (MH+) 560.2199 found 560.2209.
The intermediate 5-formyl-2-[(N-benzoyl)aminomethyl]-
benzimidazoIe was prepared as follows.
CA 02318347 2000-07-18
WO 99/41241 PCT/US99/02966
a. 5-Cyano-2-[(N-benzoyl)aminomethyl]benzimidazole. 3,4
Diaminobenzonitrile {250 mg, 1.88 mmol) was finely ground in a mortar with
(0.34 g, 1.9 mmol) hippuric acid and intimately mixed and then carefully fused
for 3 hours. The temperature was then raised to 160 °C when water was
evolved
5 as bubbles. After cooling the glassy mass was dissolved in ethyl acetate and
purified by column chromatography. (50-100%) ethyl acetate/n-hexanes yielded
86 % of pale buff colored compound; mp 131-132 °C; IR (Nujol) 2826,
2221,
1635, .1313, 1019, 814; 'H NMR (DMSO-d6 + 3 drops CF3COOH) 8 4.97
(d,2H,J=5.22), 7.52-7.61 (m,3H), 7.91-7.99 {m,4H), 8.37 (s,lH);'3C NMR
10 (DMSO-db + 3 drops CF3COOH) b 36.80, 107.73, 115.72, 118.81,
119.67127.83, 128:61, 128.64, 128.67, 128.78, 132.15, 132.20, 13322,
135.01,156.13, 167.51; HRMS (EI) calculated for C16H,ZN40 mla 276.1011
found 276.1012.
15 b. 5-Formyl- 2-[(N-benzoyl)aminomethyl]benzimidazole. S-
Cyano-2-[(N-benzoyl)aminomethyl~benzimidazole (0.33 g, 1.2 mmol) was
dissolved in formic acid (18 ml). Water (5 ml) and Ni-Al (1.14 g) were added
to
it. The mixture was heated under nitrogen at 95° C for 6 hours and
while hot
passed through a celite bed. The bed was washed with methanol and the
20 washings concentrated in vacuo. The pH of the solution was adjusted with 2N
NaOH to 9.0 and extracted with ethyl acetate. The sxtractions were dried over
anhydrous Na2S04 and concentrated in vacuo. The residue was purified over
column chromatography using (50-100 %) ethyl acetate/n-hexanes to give 26
of pure cream colored product; mp 108-109° C; IR (KBr) 3314, 2933,
1687,
25 1646, 1539, 1289, 806; 'H NMR (DMSO-d6 + 3 drops CF3COOH) 8 4.99
(d,IH;J=5.12),7.54-7.63 (m,4H), 7.93-8.07 (m,3H), 8.34 {s,lH), 10.15 (s,lH);
'3C NMR (DMSO-db + 3 drops CF3COOH) 8 36.83, 115.10; 117.18, 125.80,
127.85, 128.71, 132.26, 132.33, 133.2, 133.68, 155.77, 167.54, 192.54; HRMS
(EI) calculated for C~6Ht3N302 mlz 279.1008 found 279.1003.
Exam In a 7. 5-Phenyl-2-[2'-[2"-(2-hydroxyethyl)benzimidazol-5"-yl]
benzimidazol-5'-yl]benzimidazole (10).
CA 02318347 2000-07-18
WO 99/41241 PGT/IJS99102966
26
5-Phenyl-2-[2'-[2"-(2-methoxyethyl)benzimidazol-5"-
yl]benzimidazol-5'-yl]benzimidazole (30 mg, 0.06 mmol, Example 10) was
suspended in freshly distilled ethyl acetate (30 ml) to which was added 10
equivalence of BBr3 (0.62 ml, 1.OM) at -78 °C. After stirring at mom
temperature overnight, the reaction was quenched by adding water ( 10 ml). The
mixture was basified to pH 9.0 with ammonium hydroxide and extracted with
ethyl acetate and dried over anhydrous NazS04. The crude mixture was separated
on a chromatotron, (0-30%) methanoUethyl acetate to give 10.6 mg of the
product in 33 % yield as a brown solid. mp > 280 °C; IR (KBr) 3401,
3150,
2876, 1632, 1540, 1442, 1388, 1268, 1013, 823; 'H NMR (DMSO-d6+ 3 drops
CF3COOH) 8 3:35 (t,2H), 3.98 (t,2H), 7.42-7:56 (m,3H), 7.76 (d,2H,J=7.7),
7.85-7.98 (m,2H), 8.06-8.19 (m,3H), 8.33 (d,lH, J=8.5), 8.44 (d,lH, J=8.8),
8.73
{s,2H); "C NMR (DMSO-db+ 3 drops CF3COOH) 8 30.75, 58.09,111.71,
114.36, 114.53, 115.28, 115.98, 116.02, 118.28,119.43, 122.37, 124:71, 124.76,
125.43, 125.73, 127.40, 128.1, 129.25, 131.55, 131.64, 132.83, 133.95, 135.26,
137.79, 139.06, 139.64, 149.b7, 152.63, 156.21; HRMS (FAB) calculated for
C2~23N6~ {M~) 471.1933 found 471.1935
Fxamgl~$. S-Phenyl-2-[2'-[2"-(2-aminoethyl)benzimidazol-5"-yl]
benzimidazol-5'-yl]benzimidazole (11).
5-Phenyl-2-[2'-[2"-(2-acetamidoethyl)benzimidazol-5"-
yl)]benzimidazol-5'-yl]benzimidazole (35 mg, 0.07 mmol, Example 9) was
hydrolyzed with 2N HCl (5 ml) of 110°C for 3 hours. The cooled reaction
mixture was basified with ammonium hydroxide to pH 9.0 and purified by
column chromatography. Elution with 50:50 methanoUethyl acetate provided
75% yellow solid; mp > 280 °C; IR (Nujol) 3375, 2719, 1553,
1461,1377;'H
NMR (DMSO-db+ 3 drops CF3COOH) 8 3.45-3.52 {m,4H), 7.45-7.56 (m,2H),
7.79(d, 2H, J=7.04), 7.88-8.00 (m,2H), 8.07-8.27 (m,SH),8.42 (d,lH, J= 8.92),
8.68 {d,2H,J=4.76); "C NMR (DMSO-d6+ 3 drops CF3COOH) 8 25.52,
36.36,111.74, 113.77, 114.62, 115.33, 115.76, 116.17, 118.33, 123.75, 123.94,
124.75, 125.61; 127.48,128.16, 129:39, 131.71, 132.98, 133.11,134.77, 137.73,
138.84, 139.71, 140.12, 150.34, 153.43, 153.61; HRMS (FAB) calculated for
CZ,H,9N60 (MHO 470.2093 found 470.2089.
CA 02318347 2000-07-18
W0 99/41241 PCT/US99I02966
27
E~campl~. 5-Phenyl-2-[2'-(2"-(2-acetamidoethyl)benzimidazol-5"-
yl)]benzimidazol-5'-yl) benzimidazole (12).
S-Phenyl-2-[3,4-diaminophenyl]benzimidazole ( 124 mg, 0.41
mmol) and S-formyl-2-{2-acetamidoethyl)benzimidazole (9S mg, 0.41 mmol)
S were condensed in nitrobenzene (7 ml) overnight at 145 °C.
Nitrobenzene was
removed with the aid of a Kugekohr arid the compound purified directly by
flash
column chromatography. Elution with (1-LS %) methanol/ethyl acetate provided
69% of yellow solid; mp > 280 °C; IR (KBr) 3064, 2954, 2862, 1654,
1556,
1442, 1286; 'H NMR (DMSO-db + 3drops CF3COOH) 8 1.81 (s,3H), 3.18-3.35
(m,2H), 3.61-3.64 (m,2H), 7.45-7.6 (rn,3H), 7.79 (d,2H,J=7.04 ), 7.87-8.00
(m,2H), 8.07-8.30 {m,4H), 8.46 (d,IH,J=8.S), 8.71 (s,2H); 13C NMR (DMSO-db
+ 3 drops CF3COOH) 8 22.59, 27.89, 36.41, 111.73, 113.66, 114.59, 115.22,
115.69, 116.17, 118:61, 124.04, 125.22, 125.66, 127.47, 127.56, 128.14,
128.18,
129.36, 131.62, 131.84, 132.89, 133.69; 137.10, 138.94, 139.54, 139.68,
150:16,
1S 153.24, 155.40, 158.47, 170.27; HRMS (FAB) calculated for C3~HZSN~O {MH~)
512.2199 found S 12.2201.
The intermediate S-formyl-2-{2-acetamidoethyl)benzimidazole
was prepared as follows.
a. 5-Cyano-2-(2-aminoethyl)benzimidazole. A solution of 3,4
diaminobenzonitrile ( l g, 7.52 mmol) and (3-alanine (1.0 g, 11.3 mmol) in HCl
(8
ml, 6N) was refluxed for 24 hrs: At this time the diamine was barely
detectable
by TLC. After neutralization with 2N NaOH, the compound was directly loaded
on the column. Elution with (7S-100 %) ethyl acetate/n-hexanes and further
with
2S (1-2S%) methanol/ethyl acetate gave 46% (0.65 g) ofpure yellow compound;
mp lOS-106 °C; IR (KBr) 3438, 2855, 2734, 2212, 1625, 1569, 1483, 1457,
1385, 1222, 11 S3; 'H NMR (CD30D) $ 3.09-3.13 (m,4H), 7.49-7.66 (m,2H),
7.91 (d,IH,J=1.46); '3C NMR (CD30D) b 33.13,40.99, 106.27, 116.57, 121.04,
121.19, 127.08, 140.40, 142.59, 158.82; HRMS (EI) calculated for C~oH,oN4 m/z
186.0905 found 186.0906.
b. 5-Cyano-2-{2-acetamidoethyl)benzimidazole. S-Cyano-2-(2-
aminoethyl)benzimidazole (0.4 g, 2.IS mmoi) was refluxed in dry THF (10 ml),
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
28
acetic anhydride (0.4 ml) and triethylamine (0.4 ml) for 4 hrs. The mixture
was
neutralized with 2N NaOH and extracted with ethyl acetate to give the crude
acetamide. The acetamide was purified using flash column chromatography.
Elution with (0-15 %) methanol/ethyl acetate gave 70% of pure white
compound; mp 218-219 °C; IR (KBr} 3233, 3053, 2225, 1653, 1573; 1442,
1374, 1303, 1058, 815; 'H NMR (DMSO-d6 + 3 drops CF3COOH) 8 1.78 (s,3H),
3.26 (t,2H), 3.53-3.62 (2H, J= 6.45, 12.38), 7.89-7.95 (dd, 1H, J=1.42, 8.48),
8.00 (d, J=8.22,1 H), 8. I 9 (t, l H), 8.45 ( d,1 H, J=1.42); '3C NMR (DMSO-db
+ 3
drops CF3COOH) 8 22.57, 27.82, 36.71, 108.06, 115.52, 118.62, 119.33, 129.02,
131.29, 134.26, 156.23, 170.18; Anal. calculated for C~zH,zN40.1/4H20: C;
61.92, H; 5.41, N; 24.07 found C; 62.60, H; 5.41, N; 23.82.
c. 5-Formyl-2-(2-acetamidoethyl)benzimidazote. S-Cyano-2-(2-
acetamidoethyl)benzimidazole (94.6 mg, 0.41 mmol) was refluxed in HCOOH
(5.9 ml), water (0.5 ml) and Ni-A1 (0.4 g) catalyst for six hours . The
mixture
was filtered hot through celite and the bed washed with methanol. The washings
were concentrated in vacuo. The concentrate was basified with 2N NaOH to pH
9 and extracted with ethyl acetate. The ethyl acetate layer was dried over
anhydrous NazS04 and purified by flash column chromatography. (0-15%)
methanol/ethyl acetate gave 80% (70.10 mg) of pure white product; mp 220-221
°C; IR (KBr) 3222, 3047, 1656, 1575, 1439, 1289, 1110, 1058, 816; 'H
NMR
(DMSO-db + 3 drops CF3COOH) 8 1.79 (s,3H), 3.29 (t, 2H), 3.54-3.64 (q, J=
6.66, 12.64, 2H), 7.97-8.09 (m,2H), 8.19 (t, l H), 8.38 (s, 1 H), 10.17 (s, l
H); "C
(DMSO-db + 3 drops CF3COOH} b 22.69, 27.91, 36.75, 114.89, 116.86, 125.84,
131.67, 133.81, 135.33, 155.88, 170.13, 192.47; Anal. calculated for
C,zH13N3Oz: C; 62.32, H; 5.67, N; 18.17 found C; 62.10, H; 5.7, N; 17.92.
E~ 5-Phenyl-2-[2'-[2"-(2-methoxyethyl)benzimidazol-5"-yl]
benzimidazol-5'-yl]benzimidazole (13).
5-Phenyl-2-[3,4-diaminophenyl~benzimidazole (0.17 mg, 0.58
mmol) and 5-formyl-2-(2-methoxyethyl)benzimidazole (120 mg, 0.59 mmol)
were heated together in of nitrobenzene (5 ml) for 15 hours at 145 °C.
Nitrobenzene was removed with a Kugelrohr and the compound was loaded onto
CA 02318347 2000-07-18
WO 99141241 PCT/US9910296b
29
a column. (1-12%) methanollethyl acetate gave 80% pure yellowish product; mp
>280 °C; IR (ICBr) 3157, 2933, 1629, 1551, 1441, 1385, 1288, 1108, 818,
760,
698; 'H NMR (DMSO-d6 + 3drops CF3COOH) 8 3.33 (s,3H); 3.45 (t,2H), 3.89
(t,2H), 7.45-7.59 {m,3H), 7.79 (d,2H,J=7.04), 7.86-7.99 (m,2H), 8.06-8.14
(m,3H), 8.26-8.31 (dd,lH, J=1.34, 8.4), 8.44-8.49 (dd,lH,J=1.02,8.82), 8.72
(s,2H); '3C NMR {DMSO-d6 + 3 drops CF3COOH) 8 27.71, 58.30, 68.17, 111.7,
113.69, 114.57, 115.22, 115.72, 116.19, 118.51, 123.94, 124.21, 125.26,
125.61,
127.46, 128.14, 129.36, 131.65, 131.71, 132.91, 133.49, 137.24, 138.72,
139.68,
150.15, 153.24, 155.27; HRMS (FAB) calculated for C3~H25N6~ (MH+)
485.2089 found 485.2089.
The intermediate 5-formyl-2-(2-metl'~oxyethyl)benzimidazole was
prepared as follows.
a. 5-Cyano-2(2-methoxyethyl)benzimidazole.
I5 3,4-Diaminobenzonitrile (0.2 g, 1:5 mmol) was refluxed with (0.22 ml, 2.25
mmol) of 2-methoxypropionic acid in 4N HCl (2.5 ml) for 7 hours. After
neutralization with 2N NaOH the mixture was extracted with ethyl acetate and
dried over anhydrous NazS04 and concentrated in vacuo. The product was
purified on column chromatography using (7-100%) ethyl acetate/n-hexanes to
give a 50 % yield of pure white product; mp 122-123 °C; IR (KBr) 2875,
2225,
1624, 1544, 1454, 1288, 1215, 1106, 824; 'H NMR (DMSO-d6 + 3 drops
CF3COOH) 8 3.29 (s,3H), 3.42 (t,2H), 3.84 (t,2H), 7.87-8.00 (m,2H), 8.40
(s,lH); '3C NMR (DMSO-d6 + 3 drops CF3COOH) 8 27.65, 58.18, 68.02,
106.79, 115.56, 118.28, 119.37, 128.95, 131.31, 13.x.26, 156.12; Anal.
calculated
for C, ~ H"N3.1 /2 HZO: C; 62.84, H; 5.75, N; 19.97 found C; 62.71, H; 5.70,
N;
18.83.
b. 5-Formyl-2-(2'-methoxyethyl)benzimidazole. 5-Cyano-2-(2-
methoxyethyl)benzimidazole (0.12 g, 0.61 mmol) was mixed in HCOOH (9 mI)
and water ( 1 ml), to which was added Ni-A1 (0.6 g). The mixture was heated at
95 °C for 5.5 hours. The mixture was passed through a celite bed while
hot and
the bed was washed with methanol and the filtrate concentrated. After
neutralization with 2N NaOH and extraction with CHC13, the extracts were dried
CA 02318347 2000-07-18
WO 99/41241 PC'T/US99/0296b
over anhydrous NazS04 and concentrated in vacuo. The residue was purified by
column chromatography using a gradient of 15-100% ethyl acetate/n-hexanes to
give a white product in 65% yield; mp 83-84 °C;1R (Nujol) 2846, 2728,
1692,
1290, 1109, 816;'H NMR (DMSO-d6 + 3 drops CF3COOH) b 3.31(s,3H), 3.44
5 (t,2H), 3.86 (t,2H), 7.79-8.09 (m,2H}, 8.36 (s,lH), 10.16 (s,lH);'3C NMR
(DMSO-db + 3 dmps CF3COOH) 8 27.73,58.28, 68.08, 114.92, 116.86, 125.92,
131.55, 133.85, 135.19, 155.8, 192.43; Anal. calculated for C"H,2N202.1/4 H20:
C; 64.69, H; 5.92, N; 13.71 found C; 64.76, H; 6.02, N; 13.60.
10 F,xample 11. 5-Bromo-2-[2'-(2"-hydroxybenzimidazol-5"-yl]benzimidazol-
5'-yl]benzimidazole (18).
5-Bromo-2-[3,4-diaminophenylJbenzimidazole (33.3 mg, 0.11
mmol) and 5-formyl-2-hydroxybenzimidazole {17.7 mg, 0.11 mmol) were
heated at 145 °C in nitrobenzene (3 ml} overnight. Nitrobenzene was
removed
15 with a Kugelrohr and the compound was purified by flash column
chromatography. Elution with (5-15%) methanol/ethyl acetate gave 23.5 mg
(0.05 mmol) of yellow colored compound in 48% yield; mp > 280 °C; IR
(KBr)
3409, 3211, 1698, 1558, 1482, 1384, 1279;'H NMR (DMSO-db+ 3 drops
CF3COOH) 8 7.30 (d,IH,J=8.34), 7.69 (dd,lH, J=1.80, 8.71), 7.82 (s,lH), 7.86-
20 7.99 (m,2H}, 8.09-8.13 (m,2H}, 8.32 (dd,lH,J=1.36,8.69), 8.61 (s,lH), 11.38
(s,
1H);'3C (DMSO-db+ 3 drops CF3COOH) 8 108.01, 10.55,113.92, 115.16,
115.27, 116.25; 117.19, 117.86, 121.O1i, 122.41, 125.24, 128.70, 130.78,
132.66,
133.16, 134.85, 134.89, 135.62, 150.42, 153.09, 155.69; HRMS {FAB)
calculated for CZ,H,4BrN60 (MFi~) 445.0412 found 445.0408.
25 The intermediate 5-bromo-2-[3,4-diaminophenyl]benzimidazole
was prepared as follows.
a. 4-Brorno-o-phenylenediamine. 4-Bromo-2-nitroaniline 600 mg
(2.76 mmol) was dissolved in 25 ml absolute ethanol and 2.72 g (14 mmol)
30 SnCIZ was added. The mixture was refluxed overnight. Ethanol was removed in
vacuo and the mixture basified with 2N NaOH to pH 11. Ether extraction, drying
the ether layer over anhydrous NazS04 and concentration in vacuo afforded 486
CA 02318347 2000-07-18
WO 99141241 PCfIUS99/02966
31
mg (2.6 mmol, 94% yield) of the crude 4-bromo-o-phenylenediamine which was
used for the next step without characterization.
b. 5-Bromo-2-[3,4-nitrophenyl] benzimidazole. 4-Bromo-o-
phenylenediamine (275 mg, 1.5 znmol) and 3,4-dinitrobenzaldehyde (300 mg,
1.5 mmol) in 2 ml nitrobenzene were heated at 145 °C overnight. The
nitrobenzene was removed with a Kugelrohr. Column purification (1-10
ethyl acetate/n-hexanes) afforded 209 mg (0.57 mmol, 39% yield) of the pure
product; 'H NMR (DMSO + 3 drops CF3 COOH) 8 7.48 (dd,lH,J=1.82,8.76),
7.7 (d,lH,8.76), 7.96 (d,lH, 1.46), 8.45 (d,lH,8.5), 8.68 (dd,lH,J=1.84,8.5),
8.93
(d, l H,1.84); ' 3C NMR (DMSO + 3 drops CF3 COOH) b 116.36, 117.48, 118.66,
123.74, 127.05, 132.07, 134.49, 137.59, 140.23, 142.39, 142.81, 148.45.
c. 5-Bromo-2-[3,4-diaminophenyl]benzimidazole. S-Bromo-2-
[3,4-dinitrophenyl]benzimidazole (140 mg, 0.38 rnmol) was dissolved in 8 ml
absolute ethanol. 0.8 g SnCl2 (4.2 mmol) was added and the mixture refluxed
overnight. Ethanol was removed in vacuo and the mixture basified with 2N
NaOH to pH 11. Repeated extraction with ether, drying the ether layer over
anhydrous NaiS04 and concentration in vacuo yielded (0.11 g, 0.37 mmol) of the
crude diamine in 98% yield. The diamine was used without further purification;
'H NMR (DMSO-d6) 8 6.63 (d,lH,J=8.1), 7.26 (m,2H), 7.39 (m,2H), 6.65
(d, l H,J=1.76).
The intermediate 5-formyl-2-hydroxybenzimidazole was prepared
as follows.
d. S..Cyano-2-hydroxybenzimidazole. 3,4-Diaminobenzonitrile
(0.5 g, 3.8 mmol) and urea (0.25 g, 4.2 mmol) were heated together in 1 ml DMF
at 145-150 °C for 9 hours. The DMF was concentrated in vacuo and the
mixture
was suspended in water and extrac~ed with ethyl acetate. Purification by
column
chromatography (elution with 60/40 ethyl acetate/n-hexanes) provided (0.53 g,
3.3 mmol) a yield of 89% of the product; IR (KBr) 3533, 3209, 2224, 1732,
1482, 1281; 'H NMR (DMSU-db + 3 drops CF3 COOH) 8 7.1 (d,IH,J=8.06),
CA 02318347 2000-07-18
WO 99/41241 PC'TIUS99102966
32 .
7.09-7.41 (m,2H), 11.06 (s, l H), 11.19 (s, l H); "C NMR (DMSO-db + 3 drops
CF3 COOH) 8 102.52, 109.36, 111.61, 120.04, 126.03, 130.18, 133.93, 1SS.41.
e. 5-Formyl-2-hydroxybenzimidazole. S-Cyano-2-
S hydroxybenzimidazole (O.S g, 3.14 mmol) was mixed with Ni-A1 catalyst (3 g),
HCOOH (4S ml) and water (3 ml) and heated to reflux for 12 hrs. The hot
mixture was filtered through a bed of celite and the filtrate concentrated in
vacuo. pH of the mixture was adjusted to 9 with 2N NaOH and extraction was
carried out with ethyl acetate. The ethyl acetate layer was dried over
anhydrous
NazS04 and concentrated in vacuo. Calumn chromatographic purification, and
elution with 6S/3S ethyl acetate/n-hexanes provided 0.4 g (2.4 mmol, 76%
yield)
of the final compound; IR (KBr) 3261, 3160, 1677, 1631, 1477, 1282, 711;'H
NMR (DMSO-db + 3 drops CF3 COOH) b 7.11 (d,IH,J=8.0), 7.41 (s,lH), 7.57
(dd,lH,J=1.54,8.0), 9.86 (s,lH), 10.99 (s,lH), 11.17 (s,lH); '3C NMR (DMSO-
1 S db + 3 drops CF3 COOH) $ 108:15, 108.67, 125.37, 130.1, 130.42, 135.64,
' 1 SS.68, 191.99.
Examgle~l2. 5,6-Dibromo-2-[2'-(2"-trifluoromethylbenzimidazol-5"-
yl)benzimidazol-5'-yl]benzimidazole (22).
4,S-Dibromo-o-phenylenediamine (60 mg, 0.22 mmol) and S-
formyl-2-(2'-trifluoromethylbenzimidazol-S'-yl)benzimidazole (73 mg, 0.22
mmol) were heated in 10 ml nitrobenzene overnight at 1S0 °C. The
nitrobenzene
was removed with a Kugelrohr and the mixture loaded on a column. Elution with
90/10 ethyl acetate/n-hexanes yielded 2S mg (20% yield, O.OS mmol) of
2S compound; mp > 260 °C; 'H NMR (DMSO-db + 3 drops CF3 COOH) 8 8:02-
8.09
(m,2H), 8.14 {s,2H), 8.26-8.29 (m,2H), 8.57 (s,1 H), 8.69 (s,1 H).
The intermediate S-formyl-2-(2'-trifluoromethylbenzimidazol-S'-
yl)benzimidazole was prepared as follows.
a. 5-Cyano-2-(2'-trifluoromethylbenzimidazol-5'-
yl)benzimidazole. S-formyl-2-trifluommethylbenzimidazole (1.S g, 7 mmol)
was mixed with 0.93 g of 3,4-diaminobenzonitrile (7 mrnol) and 1 S ml
nitrobenzene. The mixture was heated overnight at 145 °C. Nitrobenzene
was
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
33
removed with a Kugelrohr and the mixture was loaded onto a column. Elution
with 40/60 ethyl acetate/n-hexanes gave 0.9 g (2.75 mmol) of the compound in
40% yield; mp > 260 °C; IR (KBr) 3254, 2916, 2223, 1614, 1175;'H NMR
(DMSO-db + 3 drops CFA COOH) b 7.74 (dd,lH,J=1.38,8.4), 7.88 (d,IH,J=8.14),
7.98 (d,1H,J=8.78), 8.25-8.03 (m,2H), 8.63 (s, lH); '3C NMR (DMSO-d6 + 3
drops CF3 COON) 8 105.62, 115.78, 116.35, 120.26, 123.06, 123.82, 127.18,
137.35, 139.65, 142.17, 142.96, 154.13
b. 5-Formyl-2-(2'-triftuoromethylbenzimidazol-5'-
yt)benzimidazole. 5-Cyano-2-(2'-trifluoromethylbenzimidazol-5'-
yl)benzimidazole (0.18 g, 0.54 mrr~ol) was refluxed in 8 ml HCOOH with 2.5 mI
water and 0.6 g Ni-A1 catalyst for 7 hours at 110 °C. The hot mixture
was
filtered through celite bed and the filtrate concentrated and its pH adjusted
to 9.0
with 2N NaOH. Repeated extraction with ethyl acetate, drying the organic layer
with anhydrous NazS04 and concentration in vacuo gave the crude product.
Purification by column chromatography (elution with 1 % methanoUethyl
acetate) yielded 87 mg (0.26 mmol, 49% yield) of the pure aldehyde; mp > 260
°C; IR (KBr) 3411, 2966, 1679, 1310, 1153; 'H NMR (DMSO-d6 + 3 drops
CF3
COOH) 8 7.96-8.06 (m,3H), 8.30-8.32 (m,2H), 8.57 (s,lH), 10.15 (s,lH);'3C
NMR (DMSO-db + 3 drops CF3 COOH) b 106.77, 112.51, 113.28, 117.79,
117.84, 118.28, 121.78, 123.96, 125.02, 132.98, 135.79, 139.62, 142.48,
153.51,
192.65.
The intermediate 4,5-dibromo-1,2-phenylenediamine was
prepared as follows, using a modif-.cation of the procedures described in U.S.
Patent Number 4,264,600.
c. 3,4-Dibromoaniline. 3-Bmmoaniline (3 g, 17.4 mmol) was
dissolved in 15 ml CHZC12 and the reaction mixture was cooled to -10 °
C in an
ice-salt bath. 2,4,4,6-Tetrabromo-2,5-cyclohexadienone, (9.29 g, 0.02 mrnol)
was added in small portions with constant stirring. The reaction mixture was
stirred for a period of 7 hours at 0 °C after which the reaction was
quenched with
2N NaOH (10 ml). The aqueous layer was extracted with CHZCIZ and the organic
layer was dried over anhydrous NazS04. The CHzCIz layer was concentrated in
CA 02318347 2000-07-18
WO 99/41241 PC'r/US99/02966
34
vacuo and purified by column chromatography. Elution with 0-3% ethyl
acetate/n-hexanes yielded 3.2 g (I2.7 mmol, 73%) of pure product; mp 80-8I
°C; IR (KBr) 3406, 3318, 3210, 1583, 1464, 1287, 1108, 860, 668;'H NMR
(CDC13) 8 6.49 (dd,lH,J=2.7,8.6), 6.7 (d,IH,J=2.64), 7.32 (d,lH,J=8.6);'3C
NMR (CDCI3) b 112.6, 116, 120.1, 125.45, 134.26, 147.08.
d. 3,4-Dibramoacetanilide. 3,4-Dibromoaniline (3.2 g, 12.7 mmol)
was mixed with 13 ml acetic anhydride and heated at I 10 °C for 2 hours
after
which it was poured over ice cold water. The aqueous layer was extracted with
ethyl acetate, O.1N HCl and 1N NaOH, and the organic layer was dried over
anhydrous NazS04. The organic layer was concentrated in vacuo and purified by
column chromatography. Elution with 1-50 % ethyl acetate/n-hexanes yielded
2.6 g (9 mmol, 71 % yield) of the acetanilide: mp 91-93 °C; IR (KBr)
3293,
3172, 1668, 1589,1552, 1522, 1373, 813;'H NMR. (CDC13} 8 2.17(s,3H), 7.33
(dd,lH,J=2.4,8.66), 7.52 (d,IH,J=8.68}, 7.87 (d,lH, J=2.4);'~C NMR {CDC13) b
25.07, 119.64, 120.35, 125.04, 125.38, 134.13, 138.40, 168.96.
e. 3,4-Dibromo-6-nitroacetanilide. 3,4-Dibromoacetanilide (2.64
g, 9 mmol) was dissolved in 8 ml conc. HZS04 (chilled in ice-salt bath) at a
temperature of 0 °C. To this solution was added 1 ml chilled nitrating
mixture
(equal volumes of conc. HZS04 and fuming HNO3) and the mixture stirred for 20
min. The reaction mixture was poured into ice water and neutralized with
ammonium hydroxide to pH of 9Ø The yellow precipitate was filtered and
purified by column chromatography. Elution with 1-4 % ethyl acetate/n-hexanes
yielded 2.1 g (6.15 mmol, 68%) of the 3,4-dibromo-6-nitroacetanilide: mp 141-
142 °C; IR (KBr) 3340, 3128, 1693, 1569, 1479, 1332, 1268;'H NMR
(CDCl3)
b 2.3 (s,3H), 8.46 (s,lH), 9.22 (s,lH};'3C NMR (CDCl3) b 26.14, 118.67,
126.86, 130.86, 134.51, 134.59, 136.98, 169.40.
f. 3,4-Dibromo-6-nitrosniline. 3,4-Dibromo-6-nitroacetanilide
(2.1 g, 6.15 mmol) was heated to refluxing temperature for 2 hours with 40 ml
of
6N HCI. The reaction mixture was then poured over an ice-water mixture and
stirred. The pH of the solution was adjusted to 9.0 with NaOH. The resulting
CA 02318347 2000-07-18
WO 99/41241 PCTNS99/02966
bright yellow precipitate was filtered, washed with cold water and dried to
yield
(1.78 g, 6 mmol, 98%) of pure pmduct; mp 204-205 °C; IR (KBr) 3475,
3355,
3097, 1612, 1478, 1241, 1122, 914; 'H NMR (CDC13) 8 6.05 (brs,2H), 7.18
(s,lH), 8.37 (s,lH);'3C NMR (CDCl3) 8 111.23,123.22, 129.34, 130.59, 133.61,
5 142.36.
g. 4,5-Dibromo-1,2-phenylenediamine. 3,4-Dibromo-6-
nitroaniline ( 189 mg, 0.64 mmol) was dissolved in 8 ml anhydrous ethanol to
which was added about 400 mg Raney Nickel. The hydrogenation apparatus was
10 at a hydrogen pressure 50 psi. After 45 min. the deep yellow color
originally
present was completely discharged indicating complete reduction of the nitro
i:o
the amine groups. The reaction mixture was filtered through celite and the bed
was washed with methanol. The methanol was concentrated in vacuo to give 135
mg of the crude diamine in 82% yield. The crude diamine was used as such
15 without further purification; 'H NMR (CDC13) 8 3.37 (br,4H), 6.93 (s,2H);
'3C NMR (CDC13) 8 113.98, 120.95, 135.84.
F~xample 13. 5-Phenyl-- 6-methoxy-2-[2'(benzimidazol-5"-yl)benzimidazol-
5'-ylJbenzimidazole (15).
20 4-Methoxy-5-phenyl-1,2 phenylenediamine (139 mg, 0.65 mmol)
and 5-formyl-2-(benzimidazol-5'-yl)benzirnidazole (170 mg, 0.65 mmol) were
heated together in nitrobenzene (5 ml) overnight at 145 °C.
Nitrobenzene was
removed with a Kugelrohr and the compound was loaded onto a column. (1-
Z O%) methanol/ethyl acetate gave 120 mg {41 %) of pure product; mp > 280
° C;
25 IR (KBr) 3298, 3050, 2987, 1630, 1541, 1438, 1283; 'H NMR (DMSO-d6 + 3
drops CF3COOH) S 3.92 (s,3H), 7.39-7.57 (m,6H), 7.72 {s,lH), 8.11-8.15
(m, l H), 8.19-8.27 (m,2H), 8.47 (dd, l H,J=1.46,8.07), 8.64 (s, l H), 8.76
(s, l H),
9.75 (s,lH); "C NMR (DMSO-d6 + 3 drops CF3COOH) 8 56.40, 95.73, 114.62,
115.18, 116.02, 116.15, 119.03, 119.07, 125.59, 126.29, 127.63, 127.67,
128.34,
30 129.79, 130.69, 131.54, 132.42, 133:38, 137.59, 148.81, 152.84, 156.82;
HRMS
(FAB) calculated for CZ$HZ,N60 (MH+) 457.1777, found 457.1770.
CA 02318347 2000-07-18
WO 99/41241 PCT1US99102966
36
The intermediate 4-methoxy-5-phenyl-1,2 phenylenediamine was
prepared as follows.
a. 4-Methoxy-2-vitro-5-phenylaniline. 3-Bromo-4-methoxy-6-
S nitroaniline (400 mg, 1.62 mmol) was dissolved in DME (20 ml).
Tetrakispalladium triphenyl phosphine (94 mg, 0.08mmol) served as the
catalyst.
To this mixture was added phenyl bomnic acid {300 mg, 1.01 mmol) and 2M
NazC03 (1.8 ml) and the mixture refluxed at 90 °C overnight. The
reaction
mixture was concentrated in vacuo and purified by flash column
chromatography. {1-10%) ethyl acetate/n-hexanes gave 280 mg (1.14 mmol) of
pure product in- 71 % yield; IR (KBr) 3435, 3328, 2933, 1570, 1480, 1227,
1029,
' 692; 'H NMR (CDC13) 8 3.80 (s,3H), 5.94 (br,2H), 6.79 (s,lH), 7.39-7.64
(m,SH), 7.64 (s,lH); '3C NMR (CDCl3;) b 56.63, 106.76, 121.26, 128.69, 128.72,
128.76, 128.79, 128.92, 129.71, 136.69, 140.24, 141.42, 148.65; MS {FAB)
calculated for C,3H,ZNZO3 244.0848, found 244.0847.
b. , 4-Methoxy-5-phenyl-1,2 phenylenediamine. 4-Methoxy-2-
nitro-5-phenyl-aniline (165 mg, 0.68 mmol) in ethyl acetate (20 ml) was
reduced
using 20 mg of 10% Pd/C as the catalyst, overnight. The mixture was filtered
through celite bed and the bed was washed with methanol. All the washings were
concentrated in vacuo to yield 139 mg (96% yield) of the crude diamine which
was used without further purification; ' H NMR (CDC13) 8 3.49 (brs,4H), 3.71
{s,3H), 6.42 (s,lH), 6.74 (s,lH), 7.26-7.52 (rn,SH);'3C NMR (CDC13) 8 56.81,
101.77, 120.93, 127.53, 128.39, 128.45, 128.49, 129.82, 129.96, 136.64,
139.17,
142.37, 153.73.
The intermediate 3-bromo-4-methoxy-6-vitro-aniline used in sub-
part a is commercially available (Aldrich Chemical Company).
The intermediate 5-formyl-2-(benzimidazol-5'-yl)benzimidazole
was prepared as described by Sun et al. J. Med. Chem. 1995, 38, 3638-3644.
CA 02318347 2000-07-18
WO 99/41241 PCT/US99I02966
37
5,6-biphenyl-2-[2'(benzimidazol-5"-yl)benzimidazol-5'-
yl]benzimidazole (16).
4,5-biphenyl-1,2-phenylenediamine (151 mg, 0.58 mmol) and 5-
formyl-2-(benzimidazol-5'-yl)benzimidazole (152 mg; 0.58 mmol) were heated
in nitrobenzene (4 ml) overnight at 145 °C under nitrogen. The
nitrobenzene was
removed with a Kugelrohr. Compound was purified by flash column
chromatography. Elution with (2-10%) methanol/ethyl acetate gave 108 mg
(0.22 mmol) of pure yellow compound in 37% yield. mp > 280 °C; IR (KBr)
3399, 3059, 1629, 1551, 1441, 1292; 'H NMR (DMSO-db + 3 drops~CF3COOH)
b 7.17-7.33 (m,IOH), 7.84 (s,2H), 8.06-8.25 (m,3H), 8.49 (dd,lH,J=1.18,8.89),
8.66 (s,IH), 8.75 (s,lH), 9.69 (s,lH); ~3C NMR (DMSO-d6 + 3 drops CF3COOH)
8 113.94, 115.24, 115.84, 116.15, 116.32, 117.89, 123.34, 126.32, 126.66,
127.86, 128.38, 128.42, 128.46, 130.05, 131.77, 131.89, 133.03, 138.87,
138.97,
140.62, 141.19, 160.97, 153.71; HRMS (FAB) calculated for C33Hz3N6 {MHO
503.1984 found 503.1989.
The intermediate 4,5-diphenyl-1,2-phenylenediamine was
prepared as follows.
a. 4,5-biphenyl-2-nitroaniline. 3,4-Dibromo-6-nitroaniline (332
mg, 1.12 mmol) was dissolved in DME {20 ml).
Tetrakis(triphenylphosphine~alladium (65 mg, 0.06 mmol), phenyl boronic acid
(200 mg, 1.64 mmol), and 2M NazC03 ( 10 ml) were added to the reaction
mixture and refluxed at 90 °C overnight. The reaction mixture was
concentrated
in vacuo and loaded onto a column. (1-3%) ethyl acetate/n-hexanes afforded 259
rng of pure yellow compound in 80% yield; mp 139-141° C; IR (KBr) 3476,
3363, 2924, 1621, 1476, 1263,1089;'H NMR (CDCI3) 8 6.11 (brs,2H), 6.86
(s,lH), 7.04-7.09 (m,SH), 7.15-7.26 (m,SH), 8.21 (s,lH);'3C NMR (CDCI3) 8
120.56, 127.22, 127.66, 128.20, 128.25, 128.52, 128.53, 129.31, 129.39,
129.47,
129.77, 130.14, 130.93, 131.79, 139.85, 139.94, 144.08, 149.03.
CA 02318347 2000-07-18
WO 99/41241 PCT/US99/02966
38
b. 4,5-biphenyl-1,2-phenylenediamine. 4,5-biphenyl-2-
nitroaniline (200 mg, 0.69 mmol) in.ethaxlol (SO ml) was reduced using 40 mg
10% Pd/C. Hydrogenation was carried out at 40 psi pressure for 10 hours. The
mixture was filtered through celite and the bed washed with methanol. The
methanol layer was.concentrated in vacuo to yield 151 mg of the crude diamine
in 84% yield. The crude diamine was used as such without purification. 'H NMR
(CD30D) 8 6.78 (s,2H), 7.01-7.16 (m, l OH); '3C NMR (CD30D) 8 118.08,
121.23, 127.17, 127.66, 130.44, 131.76, 138.32.
F=xamnle-1~. 5,6-Dibromo-2-[2'-(benzimidazol-5"-yl)benzimidazot-5'yl]
benzimidazole (20).
4,5-Dibromo-1,2-phenylenediamine (128 mg, 0.48 mmol) and 5-
formyl-2-(benzimidazol-5'-yl)benzimidazole (126 mg, 0.48 mmol) were heated
in nitrobenzene (6 ml) at 145 °C overnight. The nitrobenzene was
removed with
a Kugekohr and the mixture loaded on a column for purification. Elution with
( 1-10%} methanol/ethyl acetate gave 0:1 gm (41 %), of pure compound; mp >
260° C; IR (KBr) 3405, 3198, 1626, 1544, 1385, 1292; 'H NMR (DMSO-d6 +
3
drops CF3COOH) 8 8.03-8.13 (m,2H), 8.17 (s,2H), 8.25 (d,IH,J=9.16), 8.42
(d, l H,J=8.64), 8.59 (s, l H), 8.74 (s, l H), 9.75 (s, l H); ' 3C 1VMR (DMSO-
db + 3
drops CF3COOH) 8 114.73, 114.96, 115.77, 115.99, 118.93,;119.61, 120.73,
123.29, 124.47, 125.56, 131.49, 133.47, 134.77, 135.79, 137.95, 151.93;
152.31;
HRMS (FAB) calculated for CZ,H,3BrzN6 (MHO 506.9568 found 506.9574.
The intermediate 4,5-dibromo-1,2-phenylenediamine was
prepared as described at Example 12c-g.
Fixamnle 16- 5-Bromo-6-methoxy-2-[2'-(benzinudazol-5"-yl)benzimidazol-
5'yl] benzimidazole {21).
In nitrobenzene (4ml}, 4-bromo-5-methoxy-1,2-
phenylenediamine (123 mg, 0.57 mmol) and 5-fornlyl-2-(benzimidazol-5'-
yl)benzimidazole (150 mg, 0.57 mmol} were heated at 145 °C oveniight
under
CA 02318347 2000-07-18
WO 99/41241 PCT/US99I02966
39
nitrogen. Nitrobenzene was removed with a Kugelrohr. Chromatographic
separation (column) with (1-10%) methanol/ethyl acetate afforded 104 mg (40%)
of the title compound; mp > 280° C; 'H NMR (DMSO-d6 + 3 drops CF3COOH)
8 3.91 (s,3H), 7.17-7.29 (m,lH), 7.78 (d,lH,J=8.84), 8.00-8.13 (m,3H), 8.49-
8.53 (m,lH), 8.66 (s,lH), 8.79 (s,lH), 9.69 (s,lH);'3C NMR {DMSO-db + 3
drops CF3COOH) b 56:16, 96.43, 114.06, 114.97, 115.55, 115.79, 115.89,
116.35, 117.97, 118.42, 123.11, 125.30, 125.58, 126.33, 127.43, 131.85,
133.05,
133.11, 138.39, 140.84, 149.04, 153.44; HRMS (FAB) calculated for
CZZHI6BrN6O (MH+) The intermediate 4-bromo-
5-methoxy-1,2-phenylenediamine was prepared as follows.
a. 4-Bromo-5-methoxy-1,2-phenylenediamine: 3-Bromo-4-
methoxy-6-nitroaniline (150 mg, 0.6I mmol) (Aldrich Chemical Company) was
dissolved in ethanol (10 ml) and hydrogenation was carried out using 350 mg
Raney Nickel for 30 min. The reaction mixture was filtered through celite bed
and washed with methanol. The methanolic layer was dried in vacuo to give 127
mg of the crude diamine in 97.40% yield, which was used as such without
purification; 'H NMR (CDCI3) b 3.20 (brs,2H), 3.39 (brs,2H), 3.8 {s,3H), 8.36
(s,lH), 6.89 {s,lH); '3C NMR (CDCl3) 8 57.35, 100.38, 102:27, 122.52, 128.69,
136.68, 150.94.
Example 17. 5-(4-Chlorophenyl)-2-[2'-[2"-tritluoromethylbenzimidazol-
5"-yl]benzimidazol-5'-yl]benzimidazole (23).
2-(3,4-Diaminophenyl)-5-(4-chlorophenyl)benzimidazole
(65 mg) and 5-formyl-2-trifluoromethylbenzimidazole (43 mg) were heated
together in nitrobenzine (4 mL) at 150 °C. The nitrobenzene was removed
with a
Kugelrohr, and the crude mixture was loaded on a column. Elution with (10-
90%) ethyl acetate/hexanes gave (32 mg, 0.006 mmol) of the title compound,
30% yield; mp > 260 °C; IR (KBr) 3153, 2965, 1546,1444, 1162, 810; LJV
(MeOH) 335, 240 nm (log a = 4.45, 4.40); 'H NMR {DMSO-db + 3 drops
CA 02318347 2000-07-18
WO 99/41241 PCT/US99/029b6
CF3COOH) 8 7.56-7.64 (m, 2H), 7.73-8.06 (m, 6H), 8.17-8.25 (m, 2H), 8.33 (dd,
1H, J = 1.46, 8.81), 8.67 (d, 1H, J = 1.40);'3C NMR (DMSO-d6 + 3drops
CF3COOH) 8 114.76, 115.49, 116.00, 117.32, 117.45; 123.28, 123.89, 124.11,
125.13, 125.19, 127.45, 127.49, 129.25, 129.36, 129.42, 132.49, 133.06,
133.53,
5 136.94, 137.04, 138.23, 138.62, 140.56, 150.64, 150.84, 154.37; HRMS (FAB)
calculated for CZ$H,~C1F3N6 (MH~-529.1155 found 529.1156.
The intermediate 2-(3,4-diaminophenyl)-5-(4-chlorophenyl)-
benzimidazole was prepared as follows.
10 a. 4-(4-Chlorophenyl)-1,2-phenylenediamine. 4-(4-chlorophenyl-
2-nitroaniline (0.79 g) in a mixture of methanol:ethyl acetate (1:1, 40 mL)
was
reduced using 115 mg of 10% Pd/C. Hydrogenation was carried out at 40 psi for
10 hours. The mixture was filteres d through celite and the bed washed with
methanol. he methanol layer was condensed under vacuum to yield 0.71 g of the
15 diamine, which was used without further purification.
b. 2-(3,4-Dinitrophenyl)-5-.4-chloropheayl)benzimidazole. A
stirred solution of 4-(4-Chlorophenyl)-1,2-phenylenediamine (0.7 g) and 3,4-
dinitrobenzaldehyde (0.63 g) in nitrobenzene ( 13 mL) was heated at 150
° C
20 under nitrogen for 16 hours. The solvent was removed with a Kugelrohr and
the
mixture was purified by flash chromatography. Elution with ethyl
acetate:hexanes (I-10%) provided the benzirnidazole as a bright yellow-red
compound (0.55 g, 44%); mp 75-76 °C.
25 c. 2-(3,4-Diaminophenyl~-5-(4-chlorophenyl)benzimidazole.
2-(3,4-Dinitrophenyl)-5-(4-chlorophenyl)benzimidazole (125 mg) was disolved
in ethyl acetate (25 mL) and reduced by hydrogenation using Pd/C 10% (25 mg)
as the catalyst for 12 hours. Filtration through celite followed by
evaporation of
the solvent gave the diamine; 'H NMR (DMSO-db + 3 drops CF3COOH) b 6.92
30 (d, 1H, J=8.42), 7.57-7.62 (m, 4H), 7.65-7.$1 (m, 4H), 7.92 (s, 1H);'3C NMR
CA 02318347 2000-07-18
WO 99/41241 PCT/US99I02966
41
(DMSO-db + 3drops CF~COOH) 8 110.15, 111.28, 114.09, 115.29, 117.73,
128.18, 129.22, 129.33, 129.34, 131.87, 132.89, 132.97, 136.69, 138.68,
143.70,
150.78.
ExamRl~1$. The following illustrate representative pharmaceutical dosage
forms, containing a compound of formula I ('Compound X'), for therapeutic or
prophylactic use in humans.
(~ mgLtablet
'Compound X' 100.0
Lactose 77, 5
Povidone 15.0
Croscarmellose sodium 12.0
Microcrystalline cellulose92.5
Magnesium stearate 3,,Q
300.0
(ijl Ta, blet mg/_ tablet
'Compound X' 20.0
Microcrystalline cellulose410.0
Starch 50.0
Sodium starch glycolate 15.0
Magnesium stearate
500.0
(iii~~nsLle mg.~SapsLle
'Compound X' 10.0
Colloidal silicon dioxide1.5
Lactose 465.5
Pregelatinized starch120.0
Magnesium stearate
600.0
CA 02318347 2000-07-18
WO 99/41?,41 PCT/US99/02966
42
(ivl,~1 jection 1 f 1 m~/mll
'Compound X' (free acid 1.0
form)
Dibasic sodium phosphate 12.0
Monobasic sodium phosphate 0.7
Sodium chloride 4.5
1.0 N Sodium hydroxide solution
(pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad
1 mL
(v),~I j . ion ,~lOmg/m,~,l),~(mj
'Compound X' (free acid 10.0
form)
Monobasic sodium phosphate 0.3
Dibasic sodium phosphate 1.1
Polyethylene glycol 400 200.0
O1 N Sodium hydroxide
solution
{pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad
1 mL
(Yl,l Aerosol
'Compound X' 20.0
Oleic acid 10.0
Trichloromonofluoromethane 5,000.0
Dichlorodifluoromethane 10,000.0
Dichlorotetrafluoroethane 5,000.0
The above formulations may be obtained by conventional procedures well
known in the pharmaceutical art.
All publications, patents, and patent documents are incorporated
by reference herein, as though individually incorporated by reference. . The
invention has been described with reference to various specific and preferred
embodiments and techniques. However, it should be understood that many
variations and modifications may be made while remaining within the spirit and
scope of the invention.
